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1.1 AUTISM SPECTRUM DISORDERS 
 
 Autism spectrum disorders (ASD) describes a range of	  early-onset conditions 
classified as neurodevelopmental disorders, characterized by deficits in social 
interactions and communication, as well as by restricted interest and repetitive 
behaviors. The term “spectrum disorder” expresses the concept that, although a 
classification is generally done, the diseases are a continuum of the same condition, 
with different causes, not well-defined symptom boundaries, as well as major 
differences in developmental course, with different children manifesting sign of the 
disorder with different timing (Nolen-Hoeksema et al., 2009) (fig.1.2). The 
classification of ASD includes different pathologies like: 
• Autism 
• Asperger Syndrome (merged with autism in the new	  Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) of May 2013 [Lauritsen, 2013]) 
• Pervasive Developmental Disorder - Not Otherwise Specified (PDD-NOS). 
Rett Syndrome and Childhood Disintegrative Disorder are also listed among ASDs in 
the current version of the DSM-5, even if they might have different causes (Abrahams 
and Geschwind, 2008). 
The prevalence of ASD has been estimated in one affected child every 88 
(fig.1.1).	  ASDs are almost 5 times more common in boys (1 in 54 children) than in 
girls (1 in 252 children) (Autism and Developmental Disabilities Monitoring Network 
Surveillance, 2012), an effect that becomes even more pronounced in so-called “high-
functioning cases” (Abrahams and Geschwind, 2008). 
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Due to the communication and social deficits, affected children have problems 
in making friendships and in social relationships in general. These disorders present 
very high clinical heterogeneity, with very different pervasiveness, severity and onset, 
thus affecting life outcome in very different ways. In a study published in 2004 the 
authors followed 68 individuals that during childhood were diagnosed with ASD: in 
adult age 1/5 earned an academic diploma, five attended college and two had a post-
baccaleaureat degree, almost 1/3 had a job and 1/4 managed to have important 
friendships; however, 58% didn’t manage to live alone or to keep a job, having 
persistent communication and social deficits (Howlin et al., 2004). The poor quality 
of life and the limited understanding of the biology of autism make render the 




Figure 1.1: Prevalence of ASD affected child from 1975 to 2012 as reported from the Centers of 
Disease Control.  
 
 
1.1.1 Symptoms of ASD 
 The new-latin word “autismus” was first used in 1910 by the Swiss 
psychiatrist Eugene Bleuler, while describing the symptoms of schizophrenia. He 
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derived this word from the Greek “αύτός” (that means “self”) to describe a morbid 
self-admiration, referring to “autistic withdrawal of the patient to his fantasies, against 
which any influence from outside becomes an intolerable disturbance”. In the 40’s, 
Leo Kanner of the Johns Hopkins Hospital and Hans Asperger of the Vienna 
University hospital used this word for the first time in its modern sense: the first was 
describing 11 children, whose conditions were distinguishable from mental 
retardation on the basis of their social isolation; the second described similar patients 
affected by an “autistic psychopathy”. 
 To make an ASD diagnosis, the symptoms have to appear in the first three 
years of life. Parents usually notice the signs in the first 18 months of life, but 25%-
40% of children with ASD show near-normal development till 24 months and then 
regress to a form generally indistinguishable from early-onset autism (Werner and 
Dawson, 2005). Even if the criteria to define autism were refined since their 
formulation by Kanner, the symptoms can still be included in three core categories 
(Folstein and Rosen-Sheidley, 2001; Lam, 2007): 
 
1. Abnormalities in social development. During the first year of life, autistic 
children fail to show attachment to their primary caregivers. Later they show 
attachment, but little interest in other children. Adolescents and adults have 
awkward social interaction, like avoiding eye contact, awkward greetings and 
lack of social small talks. During conversations they usually insist in topics of 
little interest to others and don’t know when to stop speaking; 
2. Abnormalities of language development. In one-third of children with 
autism, speech never develops past the occasional word, and most of these 
children do not attempt to use other means of communicating, such as gesture 
or eye contact. The remaining two-thirds develop a varying amount of speech, 
from a few stereotyped phrases to entirely normal in structure, although not 
pragmatic (i.e. modulating speech on the basis of the context and connecting it 
to non-verbal communication). Autistic people use speech to communicate 
needs or to provide information, but rarely to exchange information, chat or 
socialize. Their speech has a monotone quality, without the natural intonation 
that aids in communication. Because language delay is not specific of ASD 
and is present in other unrelated diseases, this trait is no more used in the new 
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criteria to define ASD in DSM-5 and this core domain has been merged with 
the previous one in a social-communication domain (Lauritsen, 2013); 
3. Rigid and repetitive behaviors. Autistic children display repetitive 
movements like hand clapping, head rolling or body rocking (stereotypy). 
Sometimes these movements can also injure the person, like in the case of eye 
poking, skin picking, hand biting and head banging (self injury). They appear 
to follow rules, such as arranging objects in a certain order in a stack or line 
(compulsive behavior).  The children also become upset at being interrupted 
(sameness) and they prefer an unvaried daily routine (ritualistic behavior). 
Also, they have overly focused interests, such as playing with a specific toy 
during childhood or studying bus or train timetables, baseball statistics or 
weather forecasts during adult age (restricted behavior). 
Other features that are associated to ASD, but don’t belong to the core symptoms, 
have been reported. In fact, children with ASD can present mental retardation (in less 
than 50% of cases) and epileptic seizures (about 15%). 
 
While all the ASDs present the social impairments and the repetitive 
behaviors, Asperger syndrome affected children usually use language in an age-
appropriate manner and are not mentally retarded. Individuals with PDD-NOS, 
instead, show marked impairments in each core domain, but do not meet diagnostic 
criteria for autism. Unfortunately, diagnosis is based solely on behavior, as currently 
there are no biological markers that can be used to simplify diagnosis. Several 
diagnostic instruments are available. Two are commonly used in autism research: the 
Autism Diagnostic Interview-Revised (ADI-R) is a semi-structured parent interview, 
and the Autism Diagnostic Observation Schedule (ADOS) uses observation and 
interaction with the child. The Childhood Autism Rating Scale (CARS) is used widely 
in clinical environments to assess severity of autism based on observation of children 
(Volkmar et al., 2005) 
 
1.1.2 Causes of ASD 
When Leo Kenner described Autism in 1943 little was known about the 
causes. For decades psychiatrists thought that autism was partly due to a social 
reticence observed in parents. The mothers were labeled as “refrigerator mothers” 
even though social reticence was more common in fathers. The symptoms of an 
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autistic child were then seen as the result of a withdrawal in him/herself, preferring a 
secret fantastic world to reality (Nolen-Hoeksema et al., 2009). 
It took 20 years before researchers understood the importance of genetics in 
the aetiology of autism. The first lines of evidence are provided by the higher risk for 
a child to be diagnosed with ASD if a sibling is affected: a recent estimation addresses 
this in a 25-times higher probability than in normal population. Second, siblings and 
parents of affected children are more likely to show subtle cognitive or behavioral 
features similar to ASD-affected people. Third, independent twin studies indicated 
that the concordance rate for monozygotic twins is around 70-90%, while the one for 
dizygotic twins is 0-10% (Abrahams and Geschwind, 2008). Moreover, a number of 
other genetic syndromes manifest ASD at higher than expected frequencies compared 
to the general population: these syndromes account for more than 10% of all ASD 
cases and include tuberous sclerosis, fragile X, Down, neurofibromatosis, Angelman, 
Prader-Willi, Williams and Duchenne (Zafeiriou et al., 2013). Overall, these results 
indicate that autism is a genetic disease to such an extent that now it is accepted as the 
most genetic of all the neuropsychiatric syndromes. The causes of ASD then have to 
be searched in genes, even if some of them have to be attributed to the environment. 
Albeit the genetic component in the aetiology of ASD is clear, this disease 
cannot be connected to a single gene mutation. On the contrary, up to 100 genes and 
chromosomal abnormalities have been linked to it. Different theories have been 
postulated: some scientists have proposed a model in which up to ten loci are 
involved, with at least three of them epistatic (interacting); others instead estimated 
three to six loci, all epistatic. Even if these are just theories, what is clear is that the 
genetics of autism can’t be explained with a simple model (Folstein and Rosen-
Sheidley, 2001). 
 In the last years a big emphasis has been placed on genetic research on ASD 
and several studies have been then conducted in order to find all the genes associated 
to autism, also with the hope that knowing which processes are affected can shed 
some light in the complicate pathology of autism. Although many genes have been 
associated to autism (table 1.1 for a quick overview), none of them can account for 
more than the 1-2% of all the ASD cases.	  There are three main groups of causes in 
syndromic autism (Abrahams and Geschwind, 2008) (fig. 1.2): 
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1. Known genetic conditions such as Fragile X or tuberous sclerosis: a 
substantial proportion of individuals with these conditions show comorbid 
ASD; 
2. Cytogenetic abnormalities can be found in 6%-7% of children with ASD: 
several have been found associated to ASD (nearly on each chromosome). 
One of the most common is a duplication on chromosome 15q11–13, where 
the gene encoding for the GABA receptor is located. Other regions that are 
implicated in the ASDs by chromosomal abnormalities in multiple patients 
include	   22q13, that contains SHANK3 (a synaptic adaptor protein), 5p15, 
17p11 and Xp22, that contains NLGN4X; 
3. De novo copy number variations or single nucleotide polymorphisms 
(SNP) have been reported in 2–10% of children with ASD: among these 
important are the mutations found in NRXN1 (neurexin-1), NRXN3, NLGN3 
(neuroligin-3) and NLGN4 genes, that are proteins involved in synaptic 
function. Mutations have also been found in the CNTNAP2 (contactin 
associated protein-like 2) gene, that is a member of the Neurexin superfamily. 
Another important gene associated with autism is RELN (Reelin). 
 
 When considering the genetics of ASD another important aspect has to be 
taken into account: even thought there has been a strong presumption that the three 
cores of symptoms are strongly intertwined and proceed from a common cause at the 
genetic, cognitive and neural levels, this may not always be the case. There is 
evidence that each defect composing this disease can have a different independent 
aetiology. This would explain not only the heterogeneity of ASD, but also the high 
correlation of this disease with other neuropsychiatric syndromes (Happè and Ronald, 
2008). 
 Finally, as already stated, environmental factors have a role, even if 
secondary, in the causes of ASD. Recently, media has given a considerable attention 
to these risk factors, starting from the assumption that the incidence of autism is 
growing: even if the latter consideration was true, it has to be taken into consideration 
that this is due to the broadening of the diagnostic criteria, that lead to the inclusion in 
the ASD population of children that before would have had a different diagnosis. 
Much of the available information on the environmental risk factors reports 
association  between autism  and  pre-natal conditions, like maternal  hypothyroidism,  
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Table 1.1: Genes associated with ASD. A score was assigned to express how likely is the association 
and genes were then sorted in promising or probable, depending on the total score. AHI1, Abelson 
helper integration site 1; AVPR1A, arginine vasopressin receptor 1A; CACNA1C, calcium channel 
voltage-dependent L type alpha 1C subunit; CADPS2, Ca2+-dependent activator protein for secretion 
2; CNTNAP2, contactin associated protein like 2; DHCR7, 7-dehydrocholesterol reductase; DISC1, 
disrupted in schizophrenia 1; EN2, engrailed homeobox 2; FMR1, fragile X mental retardation 1; 
GABRB3, gamma-aminobutyric acid (GABA) A receptor beta 3; GRIK2, glutamate receptor 
ionotropic kainate 2 precursor; ITGB3, integrin beta 3; MECP2, methyl CpG binding protein 2; MET, 
met proto-oncogene; NLGN3, neuroligin 3; NLGN4X, neuroligin 4 X‑linked; NRXN1, Neurexin 1; 
OXTR, oxytocin receptor; PTEN, phosphatase and Tenascin homologue; RELN, Reelin; SHANK3, 
SH3 and multiple ankyrin repeat domains 3; SLC25A12, solute carrier family 25 (mitochondrial 
carrier, Aralar) member 12; SLC6A4, solute carrier family 6 (neurotransmitter transporter, serotonin) 
member 4; TSC1, tuberous sclerosis 1; TSC2, tuberous sclerosis 2; UBE3A, ubiquitin protein ligase 
E3A (Abrahams and Geschwind, 2008). 
 
 
maternal use of thalidomide or valproic acid, maternal use of alcohol and congenital 
cytomegalovirus, but the most compelling association is the causal link between 
congenital rubella syndrome and ASD. Also the measles-mumps-rubella (MMR) 
vaccine has been proposed as a risk factor, but the available data didn’t confirm the 
association. Moreover, a study on children born in the UK from 1979 to 1992 didn’t 
reveal any increase in ASD occurrence after the introduction of this vaccine in 1988. 
However,	  no single environmental factor has been shown to be a major contributor 
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and, given also their small	   predicted contribution, it is likely that they are only a 
“second hit” in individuals with genetic susceptibility (Folstein and Rosen-Sheidley, 
2001). 
 
1.1.3 Neuropathology of ASD 
 Several differences have been noted in autistic patients’ brains that, even if 
based on small numbers, indicate subtle, but widespread abnormalities throughout the 
cortex. MRI in young children with ASD (ages 18 months to 4 years) shows a 5%-
10% abnormal enlargement in total brain volume, increasing the size of both the grey 
and white matter. Even if also the parietal and temporal lobes seem affected, the most 
consistent increase has been reported in the frontal lobes. In these regions the space 
between the columns is reduced, a result that, coupled with the higher neuronal 
density, led to the hypothesis that there may be a greater number of neurons in the 
autistic cortex. Also the cerebellar region has been found to be bigger in autistic 
patients in an extent proportional to the brain volume. Finally, the amygdala shows an 
enlargement of 15% in 8-to-12 years old boys with autism, but doesn’t look affected 
in older subjects, maybe due to the normal growth of this brain region between 8 and 
18 years old in normal developing persons. Surprisingly, both in cerebellum and 
amygdala the neuron number seems to be lower in autistic patients compared to 
controls. Nevertheless, even if all these data show an abnormal growth of the brain, 
some studies revealed that what is disturbed in autistic patients is the time course of 
brain development rather than the final condition: the brain seems to undergo a period 
of precocious growth during early postnatal life followed by a deceleration in age-
related growth (Amaral et al., 2008). 
 So far, as suggested by the genetic findings, four major pathways seem to be 
involved in ASD pathology (Persico and Bourgeron, 2006; Geschwind and Levitt, 
2007) (fig. 1.2): 
1. Disturbed neuronal migration during the first phases of brain development, 
that can interfere with the normal development of the brain; 
2. Unbalanced excitatory to inhibitory synapses ratio: normal levels of 
inhibition are crucial for cortex development and insufficient inhibition has 
been proposed to underlie deficits in cognitive process and motor control, in 
addition to an increased susceptibility to epilepsy (Rubenstein and Merzenich, 
2003); 
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3. Axon pathfinding; 
4. Synapse formation, maintenance and pruning, as well as neuron-glia 
interaction, in which structural proteins like the Neuroligins’ and Neurexins’ 
family members can be involved. 
 
 One of the most prominent hypotheses to explain the pathobiology of ASD 
suggests that all these aberrant processes lead to an abnormal development of brain’s 
connections. In typical non-affected children the increase in brain size is due to a 
complicated and time-regulated set of events that lead to a growth of gray matter 
followed by pruning of synaptic structures and myelination. In affected children, 
instead, different sets of malfunctions, either prenatally or postnatally, lead to an 
increased local and a decreased long-distance connectivity between different areas of 
the brain, especially those involving the frontal lobe. This reduced cortical–cortical 
reciprocal activity and coupling impairs the fundamental frontal function of 
integrating information from widespread and diverse systems (emotional, language, 
sensory, etc…) that are required for a big subset of higher skills, thus favoring 
processes that require local connectivity, like visual imagination (Courchesne and 
Pierce, 2005; Geschwind and Levitt, 2007; Frith, 2004). For example, a study 
published in 2006 showed that ASD-affected children were recruiting the visuospatial 
areas of the brain for the comprehension of sentences, even when imagery was not 
required, while their not affected counterpart presented activation of the same areas 
only in the sentences that required high imagination (Kana et al., 2006). Another 
example comes from a study that	   scanned	   using functional MRI the brains of 
volunteers while they were reading a passage and answering some questions: affected 
patients were using more prominently Wernicke’s area instead of Broca’s area that is 
activated in the controls, a result that led the author to conclude that volunteers with 
ASD were concentrating on single words rather than on the sentence as a whole (Just 
et al., 2004). Due to the different subset of deficits that two affected children might 
have and to the big role that experience (and then the environment) have even on a 
normal developing brain, this developmental disconnection theory would explain why 
autism form a spectrum of diseases, with a broad range of different symptoms and 
developmental courses (fig. 1.2). Moreover, it would explain the high rate of other 
neurogenic syndromes that are often associated with ASD (Geschwind and Levitt, 
2007). 
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Figure 1.2: Scheme that summarize some of the many possible etiological features (genetic and 
environmental heterogeneity; blue circles) and the clinical or syndromic heterogeneity (green circles) 
within autism spectrum disorder, in addition to the myriad of neurodevelopmental processes that might 
be disrupted to cause disconnection (central arrowed box). Broken lines emphasize areas where the 
extent of the contribution to the disorder remains to be defined relative to the contributions made by 





1.2.1 The CNTNAP2 gene and ASD 
With the emerging knowledge on the genetic basis of ASD, several studies 
have observed that CNTNAP2 is one of the strongest candidate genes associated to 
this disease. 
 In a 2006 study on an Amish family affected by CDFE (Cortical Dysplasia-
Focal Epilepsy) syndrome Strauss et al. found a single-base deletion at nucleotide 
3709 of the CNTNAP2 gene in all the affected individuals. This frameshift mutation 
generates a premature STOP codon, truncating the protein before the trans-membrane 
domain, leading to a non-functional product. CDFE is a rare neuronal migration 
disorder resulting in epileptic seizures, language regression and, in 67% of cases, 
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ASD. Jackman et al. in 2009 reported the same mutation in an Amish girl affected by 
cortical dysplasia, focal epilepsy and autism with language regression. 
 In 2008, three other separate studies reported a correlation between the 
CNTNAP2 gene and ASD, supporting the strong role of this gene in this pathology. 
Arking and colleagues performed a linkage and association two-stage whole genome 
scan on 72 families with at least two affected children, finding a significant signal in 
region 7q35, identifying a common polymorphism in the 5’ end of CNTNAP2 gene. 
Bakkaloglu et al., instead, based on the identification of a chromosomal inversion on 
chromosome 7 that interrupts CNTNAP2 between exons 10 and 13 in a child with 
autistic features, resequenced the gene in 635 affected individuals and 942 
uncharacterized controls: they found 13 rare variants present in patients with autism, 
but not in controls, of which 8 were predicted to be deleterious or were found in 
conserved regions. Finally, Alarcòn et al. performed a study using 2758 SNPs across 
10Mb of the chromosome 7q35, finding a contribution of CNTNAP2 to the increase 
of the age of the first word that reveals a language delay in children carrying a 
mutation. Moreover, they noted an enrichment of its mRNA in brain structures known 
to be involved in language, such as the frontotemporal cortex during fetal 
development. 
 The study of Alarcòn and colleagues also lead to the hypothesis that 
CNTNAP2 can have a specific role in the development of language in the etiology of 
ASD. This idea is also supported by a study that confirmed these results using a 
different marker of language deficits, such as non-sense word repetitions, in which the 
authors excluded from the analysis any subject with autistic spectrum disorders 
(Vernes et al., 2008). Other evidence comes from the significant percentage of non-
autistic siblings of affected people that have a history of speech and language delay 
(Bolton et al., 1994). Moreover, in-situ hybridization experiments performed in brains 
of humans and rodents revealed marked differences in the expression of this gene in 
the anterior temporal and prefrontal regions of brain, where expression of CNTNAP2 
is high in humans and low or absent in rodents, reflecting the differences in the 
development and connection of these areas among these species, consistent with the 
higher language skills of humans (Abrahams et al., 2007). On the contrary, an 
expression analysis conducted on Zebra finch, a songbird that shares vocal learning 
behaviors with humans, revealed an enrichment of CNTNAP2 in cortical regions of 
the brain critical for vocal learning (Condro and White, 2013; Panaitof et al. 2010). 
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Together these data are compatible with the hypothesis that different components of 
ASD are independent and different genes can influence only some of them (Happé et 
al, 2008), with CNTNAP2 being responsible of the speech and language delays 
(Peñagarikano et al., 2012). 
 Finally, in an association study of 2010, subjects bearing variation in 
CNTNAP2 gene presented a diminished long-range anterior-posterior connectivity as 
opposed to individuals with non-risk alleles; on the contrary they showed an increased 
local frontal connectivity. The normal brain maturation, instead, is characterized by 
the weakening of short-range and strengthening of long-range cortical connectivity 
(Dosenbach et al., 2010). This relationship between CNTNAP2 genotype and 
functional connectivity was independent of autism diagnosis, indicating that this gene 
modulates a continuum of normal brain functions (Scott-Van Zeeland et al., 2010). 
Altogether these data are in agreement with the underconnectivity model proposed for 
autism (Geshwind and Levitt, 2007). 
 
1.2.2 Caspr2 is involved in other diseases 
 Mutations in the CNTNAP2 gene are found in diseases other than ASD. As 
already discussed, a frameshift mutation has been found associated with CDFE in an 
Amish family (Strauss et al., 2006). Other works confirmed this data (Jackman et al., 
2009) and demonstrated an association between this gene and schizophrenia (Clarke 
et al., 2012). 
Moreover, a complex insertion/translocation involving chromosome 2 and 7, 
disrupting the CNTNAP2 gene, has been associated with Gilles de la Tourette 
syndrome (GTS) (Verkerk et al., 2003). GTS is an inherited neuropsychiatric disorder 
characterized by repeated involuntary motor and vocal tics. It is noteworthy that this 
syndrome is also often accompanied with obsessive-compulsive disorder (OCD), 
ASD and attention deficit hyperactivity disorder (ADHD) (Clarke et al., 2012); the 
latter has also been associated to rare variants of this gene (Elia et al., 2010). It is also 
interesting that also NRXN1, a member of the Neurexin superfamily as CNTNAP2, is 
found to be associated with GTS (Clarke et al., 2012). 
Mutations in NRXN1 and CNTNAP2 have also been reported in patients with 
severe mental retardation with seizures and breathing anomalies, resembling Pitt-
Hopkins syndrome (Zweier et al., 2009). Although mental retardation is often 
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reported in children affected by ASD (<50%), its presence doesn’t belong to the three 
core symptoms (Geshwind and Levitt, 2007). 
 
1.2.3 Caspr2, a member of the Neurexin superfamily 
The CNTNAP2 gene is unusually large, spanning approximately 2.3 Mb on 
chromosome 7q35.1-q35.2; currently it is the largest known gene of human 
chromosome 7. It encodes Caspr2, a member of the Neurexin (NRXN) superfamily 
(see also par. 1.3.2). Interestingly, while the other NRXN genes have at least two 
promoters and multiple splice variants, currently there are not alternative forms of 
CNTNAP2 known (Nakabayashi and Scherer, 2001). Poliak and colleagues (1999) 
observed two bands in a Northern Blot analysis from rat brain and described two 
bands in a Western Blot analysis from the same tissue, with the lightest disappearing 
in the first postnatal week. The significance of this second form is currently unknown. 




Table 1.2: Exon-Intron structure of the CNTNAP2 gene as published by Nakabayashi and Scherer in 
2001. 
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Figure 1.3: Domain organizations of Caspr2, Caspr1, Drosophila Nrx-IV and rat αNRXN1. h: human; 
dm: drosophila melanogaster; r: rat; DISC: discoidin-like domain; LamG: laminin-G//LNS domain; 
FIB: fibrinogen similar region; PGY: A proline, glycine, tyrosin repeat; JXT: a shared juxtamembrane 
sequence, also responsible for protein 4.1 binding; PDZ: a PDZ containing protein binding domain 
(Poliak et al., 1999). 
 
 
Caspr2 was identified in 1999 by Poliak and colleagues while searching for 
Caspr1 homologs in an ESTs database. The Caspr2 open reading frame encodes for 
1331 amino-acids, with a predicted molecular weight of 130 kDa. The extracellular 
region of the protein contains 12 potential N-linked glycosylation sites, probably 
explaining the apparent molecular weight of 180 kDa that a Western Blot analysis 
gives. This region also contains 36 cysteines, likely forming 18 disulfide bonds, with 
a total of 8 independently folded domains. 
The primary sequence of Caspr2 shares 45% of identity with Caspr1; 
moreover, the protein was described as the mammalian homolog of Drosophila 
Neurexin IV (Nrx-IV), with which it shares 34% of identity. The extracellular region 
of Caspr2 is a mosaic of domains, including discoidin/neuropilin and fibrinogen-like 
domains, two EGF domains and four domains similar to a region in laminin A, 
referred to as the LamG/LNS domain. The structural organization of Caspr2 is very 
similar to both Caspr1 and Nrx-IV, all having the hallmarks of type I trans-membrane 
proteins. In fig. 1.3 a comparison between the domain organizations of these proteins 
is reported. As shown, the domain organization among Caspr1, Caspr2 and Nrx-IV is 
very similar, although the last two lack the PGY repeat found near the trans-
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membrane domain of Caspr1. But the biggest difference is found in the cytoplasmic 
domain: Caspr2 and Nrx-IV, like all the neurexins, have a short amino-acid sequence 
at their C-terminus that serves as a binding site for type II PDZ domains; this 
consensus is not present in Caspr1. Caspr1 and Caspr2 share instead the 
juxtamembrane motif, responsible for binding to protein 4.1 (Poliak et al., 1999).  
 
1.2.4 Role of Caspr2 in myelinated axons 
 Myelinating Schwann cells and oligodendrocytes ensheath the axon in 
segments separated by the nodes of Ranvier. This arrangement allows saltatory 
propagation of action potentials from node to node, improving their efficiency and 
rapidity. Myelinated axons appear thus organized in distinct domains (fig 1.4 and 
1.5): the node, the paranode, the juxtaparanode and the internode, each with a 
different function and a different set of proteins. The formation and maintenance of 
these is driven by glia. In fact, the accumulation of their specific proteins appears 





Figure 1.4: Schematic representation of action potential propagation in axon. Ensheathing glial cells 
promote saltatory propagation, providing high resistance and low capacitance, thus allowing the current 
flowing only at the nodes of Ranvier, where the action potential can be then regenerated (Peles and 
Salzer, 2000). 
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Figure 1.5: Longitudinal domains of myelinated axons in PNS and CNS. BL: basal lamina; CM: 
compact myelin sheath; PNL: paranodal cytoplasmic loops; MV: microvilli; PNP: perinodal astroglial 
processes (Peles and Salzer, 2000). 
 
 
 The node of Ranvier is devoid of ensheathing glial cells and enriched in 
voltage-gated Na+ channels, that are responsible of inward current flow and, thus, the 
regeneration of the action potential (Peles and Salzer, 2000). 
The paranode is the region next to the node; its function is to form the septate 
junction to anchor the myelin loops to the axon and to form a diffusion barrier to limit 
lateral diffusion of membrane components, confining the Na+ channels to the node 
and the K+ channels to the juxtaparanodes. One of the components of these junctions 
is Caspr1, that binds contactin 1 (CNTN1), a glycosyl-phosphatidil-inositol (GPI)-
anchored protein that belongs to the immunoglobulin superfamily (Peles and Salzer, 
2000). CNTN1 is necessary to recruit Caspr1 to the plasma membrane and for its 
targeting to the paranodes: in fact, Caspr1 alone can’t be delivered to the plasma 
membrane in CHO cells if not co-expressed with CNTN1 (Faivre-Sarraillh et al., 
2000). This complex interacts then with the 155 kDa isoform of Neurofascin 
(NF155), another immunoglobulin like protein expressed by glial cells and 
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concentrated in the paranodal loops. The Caspr1/CNTN1/NF155 complex is 
necessary for the formation of the septa (Charles et al., 2002). 
 The juxtaparanodal region is just under the compact myelin sheath, beyond the 
paranodal junction and is characterized by the presence of heteromultimers of shaker 
like K+ channel (Kv1.1 and Kv1.2, with their Kvβ2 subunit). Two main functions 
have been proposed for these channels: they can act as a direct current stabilizer to 
maintain resting potential (Chiu et al., 1999) and/or they can act as an active dumper 
for reentrant excitation (Vabnik et al., 1999). Although for the first a spatial 
localization is not necessary, for the second the enrichment at the juxtaparanodal 
locations can play an important role (Poliak et al., 2003). Caspr2 accumulates at 
juxtaparanodes, as suggested by the fact that it colocalizes with Kv1.2, and next to 
Caspr1. It also forms a complex with the K+ channels, probably through a PDZ 
domain containing protein bound to the intracytoplasmic C-terminal portion: in fact, 
an agarose-bound Caspr2 can pull down Kv1.2 from rat brain lysates, but not when it 
lacks the last aminoacid. On the contrary, the C-terminal peptide of Kv1.2, but not a 
peptide lacking the last valine, which is known to be essential for the association of 
this channel with PDZ domain containing proteins, pulls down Caspr2 from the same 
lysates (Poliak et al., 1999). Moreover, a Caspr2 null mouse shows a decreased 
accumulation of Kv1.2 at the juxtaparanodes, without affecting the total internodal 
concentration of the channel (Poliak et al., 2003). Together these data suggest a role 
for Caspr2 in the accumulation of K+ channels at the juxtaparanodes, through a non-
direct interaction. 
As stated before, the formation of the domains on a myelinated axon is driven 
by glia. Even though at the paranodes this involves the Caspr1/CNTN1/NF155 
complex, a different group of proteins should be involved at juxtaparanodes. The idea 
that emerged is that this complex is formed by Caspr2, that indirectly recruits also the 
K+ channel, and TAG-1 (Transient Axonal Glycoprotein-1, also known as CNTN2), a 
protein closely related to CNTN1, with which it shares 50% of homology and the fact 
that they are both GPI-anchored proteins. This idea emerged by the evidence that 
TAG-1 is enriched at the juxtaparanodes (Traka et al., 2002) and by the similarities of 
these two putative complexes (Caspr1/CNTN1, Caspr2/CNTN2). TAG-1 is expressed 
in many neuronal subpopulations as a GPI-anchored protein as well as a released form 
and is implicated in neurogenesis, neurite extension and fasciculation (Furley et al., 
1990). In adult mice it is expressed by both myelinating glial cells and neurons, in 
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both at the juxtaparanodal level (Traka et al., 2002). TAG-1 null mice display 
behavioral deficits, such as impaired memory and learning as well as sensorimotor 
gating and gait defects (Savvaki et al., 2008). Its amino acid sequence reveals six 
immunoglobulin C2 domains and four domains homologous to the type III repeats of 
fibronectin (FNIII) (Furley et al., 1990, see also fig. 1.6). 
 
 




In 2003, two studies published on the same issue of the Journal of Cell 
Biology (Poliak et al., 2003; Traka et al., 2003) tried to prove the binding between 
Caspr2 and TAG-1. They reported that Caspr2 null mice lose the enrichment in K+ 
channels and TAG-1 at juxtaparanodes both in CNS and in PNS, but the total content 
of the proteins between the nodes remains unaffected; Na+ channels at the nodes and 
Caspr1 at the paranodes are instead unaffected. On the other hand, TAG-1 null mice 
show a similar displacement of K+ channels and Caspr2. Interestingly no other 
morphological or functional deficit was reported in the myelinated fibers from these 
mice; also the nerve conduction seemed unaffected. Moreover, co-IP experiments on 
mice brain showed that an antibody (Ab) specific for Caspr2 can precipitate both 
TAG-1 and Kv1.2 and an Ab for TAG-1 can precipitate Caspr2 and Kv1.2 (fig. 1.7A-
B and 1.8A-B). Co-IP on transfected cells (HEK or COS) showed similar results, but 
only when the two proteins were co-transfected: in fact no association between 
Caspr2 and TAG-1 can be detected mixing two independently transfected cell lysates 
(fig. 1.7C and 1.8C-D). Finally, a soluble TAG-1-Fc fusion protein binds to cells 
expressing TAG-1 or both the proteins, but not to cells expressing only Caspr2. The 
authors interpreted all these data suggesting the model in fig. 1.9: K+ channels bind 
Caspr2 through some PDZ domain-containing proteins; TAG-1 interacts in trans with 
a molecule of TAG-1 expressed by glial cells and in cis with Caspr2, thus providing 
the structural support to localize the complex (Poliak et al., 2003; Traka et al., 2003). 
To this date, however, the Caspr2-TAG-1 complex hasn’t been yet characterized. 
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Figure 1.7: WB describing the association of Caspr2 to TAG-1 as published by Poliak et al. 2003. A 
and B: WB analysis on proteins immunoprecipitated from rat brain lysate; C: WB analysis on proteins 
immunoprecipitated from HEK cells co-transfected with the specified proteins. Caspr2 and TAG-1 
seem to interact with Kv1.2 (A and B) and directly bind to each other (C), but not interact with the 





Figure 1.8: WB describing the association of Caspr2 to TAG-1 as published by Traka et al., 2003. A 
and B: WB analysis on proteins immunoprecipitated from rat brain lysate; C and D: WB analysis on 
proteins immunoprecipitated from HEK cells transfected with Caspr2, TAG-1 or both. As before 
Caspr2 and TAG-1 seem to directly bind to each other. 
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Figure 1.9: Schematic representation of the model proposed for K+ channel/Caspr2/Tag-1 complex at 
the juxtaparanode (Poliak et al. 2003). 
 
 
Another important intracellular ligand of Caspr2 is protein 4.1B. The latter is 
enriched all along the axon, with the exception of the Node of Ranvier and can bind 
the intracellular domains of both Caspr1 and Caspr2. A recent study showed that 
protein 4.1B knockout mice present in the sciatic nerve a decreased and altered 
distribution of Caspr1 to the paranode and an almost complete loss of Caspr2, TAG-1, 
Kv1.1 and Kv1.2 at the juxtaparanodes. Once again, the total amount of the protein 
was unaffected, reflecting a lack of their enrichment at the right site and not a protein 
destabilization. Moreover, the paranode appeared non homogeneous and with less 
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clearly defined limits than in WT mice, that lead to the mislocalization of the 
juxtaparanodal K+ channels to the paranode. The protein 4.1 family members are 
known to bind spectrin, a component of the intermediate filaments, so it can form a 
bridge between Caspr1 or Caspr2 and the cytoskeleton, revealing the importance of 
this protein in the stabilization of the paranodal and juxtaparanodal regions 
(Cifuentes-Diaz C et al. 2011). 
 
1.2.5 Other Caspr2 localizations 
 Although the presence of Caspr2 at the juxtaparanodes has been well 
established, little is currently known on CASPR2 subcellular localization in the CNS 
(Poliak et al., 1999; Inda et al., 2006; Bakkaloglu et al., 2008; Ogawa et al., 2008; Bel 
et al., 2009; Zweier et al., 2009). 
It has been reported that Caspr2 is enriched at the axon initial segment (AIS) 
of pyramidal cells (Inda et al., 2006; Ogawa et al., 2008). This region is innervated by 
chandelier’s terminals and it is therefore devoid of myelin. Chandelier cells are a 
particular type of GABAergic interneuron and alteration in its connectivity has been 
associated with syndromes such as epilepsy and schizophrenia. In contrast to the 
axon, the AIS present only a partial segregation of Na+ and K+ channels (Inda et al., 
2006). Interestingly, Caspr2 colocalizes with K+ channels, but is not required for its 
localization at the AIS (Ogawa et al., 2008). 
 Some evidence is reported on the expression of Caspr2 at synaptic 
compartments. A subfractional analysis on rat lysates found Caspr2 and TAG-1 in the 
fraction containing synaptic plasma membrane (Bakkaloglu et al., 2008).  
Immunocytochemistry data showed a signal in cells bodies and dendrites in rat 
hippocampal neurons (Poliak et al., 1999). However, a 2009 study found a polarized 
expression of Caspr2 in these neurons, showing how Caspr2 is rapidly internalized in 
the somatodendric compartments, but not in the axon (Bel et al., 2009). Finally, a 
work in Drosophila points to a localization of Nrx-IV (the orthologous protein of 
Caspr2) to the pre-synaptic compartment, a finding consistent with the association to 
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1.3 NEUREXINS AND NEUROLIGINS 
 
1.3.1 Neurexins and Neuroligins in ASD 
 As ASD has been proposed to result from disconnections of brain regions, that 
disrupt a higher order association in favor of an increased local connectivity (Kana et 
al., 2006; Geshwind and Levitt, 2007) it is clear that synapse function and plasticity, 
playing a key role in neuron-neuron contact, have to be important in the development 
of these diseases. Among the synaptic proteins two classes have been proposed to be 
responsible for the function of the synapse, its specialization (excitatory or inhibitory) 
and the asymmetric differentiation of the branches of the two involved cells: these are 
the neurexins’ (NRXN) and neuroligins’ (NLGN) families of adhesion proteins. It is 
not therefore surprising that several studies found an association between ASD and 
these genes, in particular NRXN1, NLGN3, NLGN4 and NLGN4Y (Südhof, 2008). 
 Regarding the NRXN family, Feng et al. reported in 2006 two missense 
structural variants of NRXN1-β in ASD-affected subjects not present in healthy 
controls. Moreover, missense mutations or splice variants also of the isoform 
NRXN1-α were found in another case control study in 2008 (Yan et al., 2008).	   In	  those	   years	   several	   other	   point mutations, translocation events and large-scale 
deletions in the NRXN1 gene were detected in patients with autism (Szatmari et al., 
2007; Kim et al., 2008; Zahir et al., 2008; Marshall et al., 2008). 
 The first evidence linking a mutation in a member of the NLGN family to 
ASD was reported in 2003 by Jamain et al. Starting from the evidence of de novo 
rearrangements in Xp22.3 they identified the transcripts of NLGN4. Noting that 
NLGN3, another member of the family, maps to Xq13.1, a region also known to be 
rearranged in autistic subjects, they screened for mutations of these two genes in 36 
affected siblings pairs and 122 trios. They found in each gene a frameshift mutation 
segregating in two Swedish families. In the following years, several other studies 
reported mutations in NLGN3, 4 and 4Y (Laumonnier et al., 2004; Talebizadeh et al., 
2006; Yan et al., 2005; Lawson-Yuen et al., 2008; Zhang et al., 2009), strengthening 
the idea that this class of proteins can be involved in the pathogenesis of ASD. 
Other insights linking these proteins to ASD come from experiments on 
animal models. In some studies, in fact, autism-like phenotypes were observed in the 
KO animals for either NLGNs or NRXNs. Mice lacking NLGN1 showed impaired 
spatial memory, reduced Long Term Potentiation (LTP) in hippocampus and spent 
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more time in grooming than their wild type counterparts: the latter is likely to be the 
result of increased repetitive behaviors, that is one of the core symptoms of ASD 
(Blundell et al., 2010). On the other hand, mice lacking NRXN1 showed the same 
increased grooming phenotype seen in NLGN1 knock out mice (Etherton et al., 
2009). When NLGN2 was deleted instead, the mice showed an increased anxiety-like 
behavior and decreased pain sensitivity (Blundell et al., 2009). Deletion of these 
genes leads also to impairments in sensory processing in honeybees and C. elegans 
and in long-term memory in Aplysia (Knight et al., 2011). Finally, SHANK3, another 
intracellular scaffolding protein that can bind to NLGNs through PSD95 and GKAP, 
has been found associated to ASD, further strengthening the evidence of the 
association of the NLGNs’ family to this disease (Südhof, 2008). 
Another aspect that makes the association of these proteins with ASD 
important is the localization of NLGN3, NLGN4 and NLGN4Y at the sexual 
chromosomes. This can, at least in part, explain why ASD has a higher incidence in 
male rather than in female subjects. 
 Like Caspr2, these genes also have been found associated to other diseases, 
like Tourette’s syndrome (Lawson-Yuen et al., 2008), mental retardation 
(Laumonnier et al., 2004) and schizophrenia (Kirov et al., 2008). This is not 
surprising because of the important role that they exert in the synaptic junction: at this 
level a similar molecular alteration can produce different changes depending on the 
circuit involved, leading then to different neurological symptoms, which can be 
classified as distinct cognitive diseases. Consistent with this, two family members 
carrying the same mutation can present different cognitive disorders (Südhof, 2008).  
 
1.3.2 Neurexins and Neuroligins: two synaptic adhesion proteins 
 Neurexins (NRXNs) are a class of type I membrane proteins, firstly identified 
as a receptor for α-latrotoxin, a component of the venom of the black-widow spider 
(Ushkaryov et al., 1992). They can be classified in two types: α- and β-NRXNs. The 
N-terminal extracellular portion of α-NRXNs presents six LNS domains (a repeat of 
Laminin, NRXN, Sex-hormone-binding globulin domains), intercalated by three EGF 
(epidermal growth factor) like domains, whereas β-NRXNs have only a short specific 
sequence and the last LNS domain. The two types of proteins have identical stalk 
domains, rich in O-glycosylated residues, transmembrane and the intracellular C-
terminal domains, that present a PDZ binding motif (fig. 1.10) (Südhof, 2008). 
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Figure 1.10: Domain organization and splicing sites of NRXNs and NLGNs. In the table are also 
reported the number of different variants available for each splicing site. L: LNS domains; E: EGF like 
domains (Südhof, 2008). 
 
 
 The human genome contains three NRXN genes, mapping at 2p16.3, 11q13 
and 14q31 respectively. Neurexins are highly conserved in mammals, with more than 
95% sequence identity between species (Missler and Südhof, 1998). Each gene codes 
an α- and a β-NRXN, starting from different promoters and all three are also 
extensively spliced during transcription: the α-NRXN genes each contain five splice 
sites (SS1 to SS5), but only the last two are shared with β-NRXNs (SS4 and SS5). 
These splice sites are used independently of each other and each one has several 
Section 1  Introduction _____________________________________________________________________________________________	  
	   25	  
alternative variants (fig. 1.10), generating virtually thousands of possible different 
proteins. Moreover, both the expression of the six NRXNs and the alternative splicing 
vary between different brain regions, raising the combinations available (Ullrich et 
al., 1995). 
Immunofluorescence data show that NRXNs are located on pre-synaptic 
terminals, but it’s not clear if they’re confined there, because deletion of genes 
encoding α-NRXN has also post-synaptic effects (Südhof, 2008). Moreover, NRXN3 
has been found outside the brain (Occhi et al., 2002) and one of its splice variants 
lacks the transmembrane domain and can be thus released (Missler and Südhof, 
1998). 
 Neuroligins (NLGNs) are also a class of type I membrane proteins. They were 
identified due to their ability to bind NRXNs (Ichtchenko et al., 1995). The 
extracellular N-terminal part of NLGNs shows a single domain, that is homologous 
with acetylcholinesterases, but it lacks residues crucial for the active site, resulting 
thus in a disabled activity. A stalk domain, rich in O-glycosylated residues, a 
transmembrane and an intracellular C-terminal domain follow (fig. 1.10). Similar to 
NRXNs, NLGNs also have a type I PDZ binding motif in their intracellular domain 
(Südhof, 2008). 
 There are five genes encoding for NLGNs in the human genome, mapping at 
3q26.31, 17p13.1, Xq13.1, Xp22.3 and Yq11.221 respectively: the latter, reported 
either as NLGN4Y or as NLGN5, complements NLGN4 on the Y chromosome, 
sharing with it a very high homology. NLGNs, as NRXNs, are highly conserved: for 
the same member of the family the sequence identity among mammals is 98%. 
NLGNs have only one splicing site (SSA) plus a second one present only in NLGN1 
(SSB): both have multiple alternative variants, even if in a less amount than NRXNs’ 
(fig. 1.10). Sequence comparison indicates that NLGN1, NLGN3 and NLGN4/4Y are 
more similar to each other than to NLGN2 (Südhof, 2008). 
NLGN1 is exclusively localized in excitatory post-synaptic terminals, as it can 
colocalize with glutamate, but not GABA receptors (Song et al., 1999); the opposite 
result is observed with NLGN2, showing that it localizes at the inhibitory post-
synaptic terminals (Varoqueaux et al., 2004). NLGN3 on the other hand colocalizes 
with NLGN1 and glutamatergic markers as it does with NLGN2 and GABAergic 
markers, showing thus localization both in excitatory and in inhibitory post-synaptic 
terminals (Budreck and Scheiffele, 2007). NLGN3 has been found also in many 
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classes of glial cells, particularly olfactory ensheathing glia, suggesting the possibility 
that it mediates glia-glia and glia-neuron interactions (Gilbert et al., 2001). NLGN4 
accounts for 3% of NLGN proteins in mouse brain, thus its exact localization is yet 
unknown (Varoqueaux et al., 2006). A northern blot study detected NLGN4 also 
outside the brain, but its role there is still unknown (Bolliger et al., 2001). 
 
1.3.3 The Neurexin-Neuroligin complex 
 The synapse is the asymmetric site of neuron-neuron contact that permits the 
transmission of a signal from one cell to the other. On the presynaptic side it is 
formed by an active zone for neurotransmitter release, a network of scaffolding 
proteins and a cluster of neurotransmitter containing vesicles; on the postsynaptic site, 
instead, there are scaffolding proteins and a cluster of neurotransmitter receptors 
placed on the membrane opposed to the active zone of release. Between the two 
membranes there is a 20 nm wide extracellular space that separates the 2 neurons, 
where several proteins are located. In this space the binding of Neurexins and 
Neuroligins occurs, forming an interaction layer, separated from the two plasma 
membranes by the glycosylated linker regions of these proteins. 
 NLGNs bind both α- and β-NRXNs with nanomolar affinities (Comoletti et 
al., 2006). Two molecules of NLGN dimerize through a four helix bundle, formed by 
two helices from each acetylcholinesterase-homolog domain and the connecting 
sequence between the globular lobes of the dimer and the cell membrane is elongated, 
projecting away from the dimer interface (Comoletti et al., 2007). Two molecules of 
NRXN bind, instead, to the opposite faces of the central dimerization site. The 
binding surface is then formed from the sixth LNS domain of α-NRXNs, that 
corresponds to the only LNS of the β-NRXNs, and the esterase homology domain of 
NLGN in a position opposite to the crippled acetylcholinesterase site (fig. 1.11). In 
each of the two binding interfaces two Ca2+ binding sites coordinated by residues 
from both proteins can be found, explaining thereby the calcium dependence of this 
association (Araç et al, 2007). 
The splice site SSB of NLGN1 is included in the binding interface and SSA is 
close to SS4 of NRXN1. This observation can provide a structural reason for the 
effect of alternative splicing on the binding affinity of the complex. In fact, the 
affinities between NRXNs and NLGNs are variable and are controlled from the splice  
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Figure 1.11: The NLGN1-β-NRXN1 complex seen in two orientations. Left: en-face, to illustrate the 
NLGN1 dimer. Right: 90° rotation to illustrate the binding (Comoletti et al., 2007). 
 
 
variants that are included in the molecules: in this way, through the post-
transcriptional event of splicing, a recognition code that can modulate synapse 
plasticity and development is generated (table 1.3). For example, the presence of SSB 
in NLGN1 restricts the binding of this protein only to β-NRXNs that lack SS4, but the 
lack of those eight residues leads to the binding of both α- and β-NRXNs, regardless 
of SS4 (Boucard et al., 2005). The lack of SSA in NLGN1, instead, leads to a 
decreased affinity for β-NRXN1 lacking SS4, but to a smaller extent. Moreover, the 
presence of SS4 of β-NRXN1 seems to alter the rank order of selectivity for different 
NLGNs: unlike NLGN1, in fact, NLGN2 and NLGN4 display a slight preference for 
β-NRXN1 that has SS4, rather than the one lacking it (Comoletti et al., 2006). Finally, 
of interest is the recent finding that the alternative splicing of NRXNs can be driven 
by synaptic activity: under depolarizing condition the mRNAs of NRXNs lacking SS4 
increase, while the ones carrying that sequence are decreased, in a process that 
involves calcium/calmodulin-dependent kinase IV signaling and the protein SAM68. 
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In this way the activity of the neuron can shift the NRXNs’ ligand preference from 




Table 1.3: Summary of the code of binding between different splice variants of NRXNs and NLGNs 
(Bang and Owczareck, 2013). 
 
 
 Recently, other proteins have been found to bind NRXN or NLGN. For 
example, leuchine-rich repeat transmembrane (LRRTM) neuronal proteins bind β-
NRXN1 lacking SS4 with a Kd of 20nM. Moreover, both NLGN an NRXN bind 
receptor like protein tyrosine phosphatases (PTPRT). As a result, other proteins can 
regulate synapse formation. 
 
1.3.4 Biological role of the complex 
 The first evidence for the role of NLGN and NRXN in synapse came from the 
work of Scheiffele and colleagues in 2000. They showed that overexpressing either 
NLGN1 or NLGN2 proteins in non-neuronal cells was possible to trigger the 
formation of pre-synaptic structures in contacting neurons. This effect was specific, 
because an excess of soluble β-NRXN could oppose it. Moreover, using NLGN-
coated beads instead of cells or artificially clustering NRXNs by specific antibodies 
the same results can be obtained, suggesting that this effect is due to neuroligins’ 
potential of clustering neurexins (Dean et al., 2003). These findings were then 
complemented by the observation that non-neuronal cells expressing NRXNs proteins 
could induce the formation of both GABAergic and glutamatergic post-synaptic 
specialization in neurons. As for NLGN, NRXN-coated beads can exert the same 
effect (Graf et al., 2004). Finally, RNA interference-mediated down-regulation of 
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NLGN1, NLGN2 and NLGN3 in cultured neurons reduces the number of excitatory 
and inhibitory synapses (Chih et al., 2005); the same effect can be achieved using 
soluble β-NRXN to block the NLGN-NRXN association (Levinson et al., 2005). 
 Together these results led to the conclusion that the binding between NLGN 
and NRXN may induce synapse formation, but analysis of gene knock-out mice 
proved that this is not the case. In fact, mice lacking NLGN1, NLGN2 and NLGN3 
die at birth, but they all have a normal synapse number. The respiratory failure that 
leads to death is instead a consequence of reduced GABAergic and glutamatergic 
synaptic function that leads to an abnormal network activity in brainstem centers that 
control respiration (Varoqueaux et al., 2006). The deletion of all three α-NRXNs 
leads to a reduction in the density of synapses and to the impairment of the machinery 
that regulates the release of synaptic vesicles (Missler et al., 2003). It is then 
reasonable to think that NLGN-NRXN binding is necessary for synapse maturation, 
instead of synapse formation, and that the results reported before reflect more the 
stabilization of otherwise transient synaptic contacts. The extracellular NLGN-NRXN 
binding triggers a set of signals both at the pre-synaptic and the post-synaptic level, 
activating functions specific for the different localizations and the different kind of 
synapse, that can also be modulated by the neuronal activity (Südhof, 2008). 
 These signals generated by the extracellular binding are bidirectional and pass 
through the intracellular domains of NLGNs and NRXNs, that can recruit intracellular 
proteins, like those containing PDZ regions (fig. 1.12). NLGNs and NRXNs bind 
different proteins, exerting different functions: in this way, their binding can trigger 
the formation of the asymmetric junction. 
NRXNs bind protein 4.1 and the class II PDZ domain of CASK. The latter is a 
MAGUK (membrane-associated guanylate kinase) protein composed by two regions: 
the C-terminal contains PDZ, SH3 and guanylate-kinase domains, while the N-
terminal has a Ca2+/calmodulin-dependent protein kinase (CAMK) that shows a 
Mg2+ independent activity. CASK can phosphorylate NRXN and bind to protein 4.1, 
VELI and MINT proteins, nucleating the assembly of actin on the cytoplasmic 
sequence of NRXN, that can in turn trap and stabilize clusters of synaptic vesicles 
(fig. 1.12). Moreover, CASK and MINT both contain multiple PDZ domains and can 
therefore recruit a larger scaffold of protein, with additional NRXNs, to form a large 
adhesive contact (Butz et al., 1998; Dean and Dresbach, 2006; Südhof, 2008). In this 
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way, CASK can translate the extracellular signal of NLGN-NRXN binding to an 





Figure 1.12: Schematic representation the asymmetric contact site generated by the NRXN:NLGN 
binding at the excitatory (A) or inhibitory (B) synapses (Bang and Owczareck, 2013). 
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 In glutamatergic synapses, NLGN1 binds to class I PDZ domains such as 
those contained in PSD-95, a post-synaptic MAGUK protein. This protein contains 
different PDZ domains and each one is specialized for a distinct function, enabling 
PSD-95 to bind both NLGN1 and NMDA channels (Irie et al., 1997). Moreover, 
PSD-95 can bind to other proteins, especially to GKAP, which, in turn, binds to 
SHANK, bridging the recruitment of scaffolding proteins at the post-synaptic site, 
including the cytoskeleton (Sheng and Hoogenraad, 2007). PSD-95 has been 
proposed to have a role on the balance of excitatory and inhibitory synapses: its 
overexpression can in fact lead to a reduction of inhibitory synapses and an increase 
of the excitatory ones, while its suppression has the opposite effect (Prange et al., 
2004; Dean and Dresbach, 2006). The maturation of glutamatergic synapses passes 
through a two-step process. The initial contact between axon and dendrite leads to the 
accumulation of NLGN1 and NMDA receptors on the post-synaptic side. As a second 
maturation step, the NLGN1-PSD-95 complex recruits AMPA receptors to the post-
synaptic membrane (fig. 1.12A). This process requires synaptic activity: specifically 
the recruitment of GluR1-containing AMPA receptor requires synapse activity, 
whereas GluR2-containing AMPA receptors accumulate also in resting conditions. 
The importance of the synapse activity is also exhibited by the potential of NMDA 
co-agonist in rescuing the abnormal grooming behavior showed by NLGN1 null mice 
(Blundell et al., 2010). Finally, while GluR1 seems to be inserted on the synaptic 
membrane at the sites of NRXN-NLGN binding, GluR2 is trapped at that site through 
a mechanism dependent on NLGN1-PSD-95 interaction. The overexpression of 
NLGN3 in neurons, instead, enhances AMPA, but not NMDA receptor-mediated 
currents, suggesting that NLGN3 can also play a role in the unsilencing of the 
excitatory synapses (Bang and Owczareck, 2013).  
 In GABAergic synapses, NLGN2 is involved in the recruitment of gephyrin 
and collybistin that are two key components of the inhibitory postsynaptic scaffold: 
the first is critical for GABA receptors’ localization, while the second, when 
activated, tethers gephyrin to the postsynaptic membrane (fig. 1.12B). Thus, NLGN2 
can drive the clustering of GABA receptors (Bang and Owczareck, 2013). It has been 
shown that also the refinement of developing GABAergic synapses depends on 
activation of NMDA receptors and that this induces a down-regulation of the receptor 
itself (Gillespie et al., 2005). 
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NRXN isoforms can play a role in the specification of the synapses’ 
properties: α-NRXNs seem to be primarily expressed by GABAergic synapses, 
whereas β-NRXNs localize also to the glutamatergic ones. Moreover, α-NRXNs and 
β-NRXNs with SS4 induce specifically the formation of GABAergic synapses (Chih 
et al. 2006). Fu and Huang (2010) proposed a model in which α-NRXNs, that can 
diffuse along the axon membrane, can function as an exploring mechanism, searching 
for post-synaptic partners. The first α-NRXN-NLGN weak binding can recruit CASK 
and the presynaptic release machineries. Synapse-specific β-NRXNs are then 
delivered to the presynaptic membrane, engage in high affinity binding with the 




1.4 OTHER PROTEINS IDENTIFIED IN THE WORK 
 
1.4.1 Secreted Frizzled Related Protein 1 
 Secreted Frizzled Related Proteins (SFRPs) is a family of five secreted 
proteins, widely expressed in human tissues. The protein structure (fig. 1.13) involves 
an N-terminal Cysteine-Rich Domain (CRD) and a C-terminal Netrin-Like domain. 
The CRD domain, usually called the Frizzled domain, is homologous to the 
extracellular portion of Frizzled (Fz) receptors, sharing with them about 50% of 
identity, including the ten key cysteines that are highly conserved residues. The 
Netrin-like domain, instead, is also present in other proteins, where it appears to bind 
heparin and function in the inhibitory activity of these molecules against extracellular 





Figure 1.13: Protein structure of Secreted Frizzled Related Protein 1. Red line: leader peptide; Fri:	  
Frizzled domain; C345C: Netrin domain, found also in complement proteins C3, C4, and C5. 
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 The known mechanism of action of SFRPs is due to their CRD domain. The 
homology with Fz receptors can let them bind the ligands without provoking a signal 
cascade. Moreover, the CRD of SFRPs seems able to dimerize with the corresponding 
domain both in other SFRPs and Fz receptors. Therefore, because these receptors are 
involved in the Wnt signaling, SFRPs are involved in its modulation, having then a 
role in regulation of cell growth and differentiation in specific cell types. The 
proposed models of action are: 1) sequestering Wnts; 2) acting in a negative-dominant 
fashion through the formation of inactive complexes with Fz receptors that prevent 
signal activation; 3) favoring Wnt-Fz interactions by simultaneously binding to both 
molecules and promoting signal activation. Depending on their mechanism of action 
different SFRPs can either favor or oppose Wnt signaling, exerting opposite 
functions. For example, while SFRP1 blocks the Wnt mediated stabilization of β-
catenin and promotes cell-death, SFRP2 promotes β-catenin accumulation and 
increases cell resistance to apoptosis (Bovolenta et al., 2008). 
 Another role exerted by SFRP1 that does not depend on its ability to bind the 
Wnt, but only the Fz receptor, is axon guidance.	   SFRP1 can directly modify and 
reorient the growth of retinal ganglion cell growth cones: it requires pertussis-toxin-
sensitive activation of Ga protein, it involves protein synthesis and degradation, and it 
is modulated by different levels of cAMP and cGMP (Rodriguez et al., 2005). 
 Other than its role performed by the binding to Wnt and Fz receptors, SFRPs 
appear to be promiscuous proteins that can interact with molecules that are unrelated 
to components of the Wnt signaling cascades and among which there is no apparent 
relationship. These include fibronectin, Unc5H3, receptor activator for nuclear factor 
kappa B (NF-κB) ligand (RANKL) and bone morphogenetic protein (BMP)/Tolloid 
(Bovolenta et al., 2008). 
 Wnt proteins were first identified as mammary oncoproteins. Indeed, aberrant 
activation of canonical Wnt signaling occurs in a large proportion of tumors, and is 
associated with the loss of controlled growth and the impairment of cell 
differentiation. In line with a tumor suppressor function of SFRPs, loss or significant 
down-regulation of SFRP1 expression has been observed in a large proportion of 
invasive carcinomas (Bovolenta et al., 2008). Interestingly, deregulation of the Wnt 
pathway has also been posited as central to the pathogenesis of Alzheimer’s disease 
(AD), potentially at the level of β-catenin or GSK-3b activity through altered 
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interactions with the presenilin proteins (which are mutated in familial AD) (Jones 
and Jomary, 2002). 
 
1.4.2 Clusterin 
Clusterin (CLU, also known as Apolipoprotein J or APOJ) is a secreted 
protein expressed in almost all mammalian tissues but with higher expression level in 
brain than in many other tissues. The structure of CLU presents two large domains 
(fig. 1.14) that are cleaved during the maturation of the protein and remain bound by 
five disulfide bridges. The protein is highly glycosylated, with carbohydrate 
accounting for approximately 20-25% of the total mass of the mature molecule 
(Stewart et al., 2007). In general, both the structural and functional characteristics 
strongly indicate that the main function of CLU is to act as a chaperone molecule. 
CLU contains three amphipathic and two coiled-coil α-helices, which are typical 
structures for molecular chaperones. Interestingly, the secondary structure of CLU 
also contains three large intrinsic disordered regions, i.e. molten globule domains. 
Molten globule regions are flexible, protein–protein interacting domains present in 





Figure 1.14: Protein structure of Clusterin. Red line: leader peptide; CLa: Clusterin Alpha chain; CLb: 
Clusterin Beta chain. 
 
 
CLU is an ATP-independent type of chaperone, which with its molten globule 
domains confers broad substrate specificity. CLU does not refold the proteins, but 
stabilizes stressed proteins into a state that is suitable for refolding. Fig. 1.15 provides 
a summary of the known roles of CLU in Alzheimer’s disease, in which it acts as a 
versatile pro-survival factor which has few, if any, harmful characteristics. In fact, in 
brain CLU is involved in clearance of Amyloid-β (Aβ) protein. It can either prevent 
Aβ oligomerization or enhance the formation of fibrillar structures, depending on the 
ratio between clusterin and Aβ peptides. Moreover, by binding LRP-2/megalin (low-
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density lipoprotein receptor-related protein-2) it is involved in the clearance of the Aβ 
peptides through the blood–brain barrier (BBB). Finally, Clusterin can also inhibit the 
activation of the complement system. This is an important property since several 
studies have demonstrated that protein aggregates can activate the complement 
system and provoke inflammatory responses in AD (Nuutinen et al., 2009). 
Other than its role in AD, CLU, as other apolipoproteins, is included in lipid 
particles that transport lipids, e.g. cholesterol and phospholipids, in body fluids. In 
this role its main binding partner is apolipoprotein A-I in HDL. The major difference 
between CLU and other apolipoproteins is that the former is present in lipid-poor 
particles (Nuutinen et al., 2009). 
 
 
           
 
Figure 1.15: The functions of Clusterin and Apolipoprotein E chaperones in Alzheimer's disease. 
 
 
1.4.3 Apolipoprotein E 
 Apolipoprotein E (APOE) is a secreted protein produced predominantly from 
the liver, where the bulk of plasma APOE originates, and from the brain, which has a 
different pool of this protein, because it cannot pass the blood–brain barrier. In the 
lipid-free state, the structure of APOE is similar to the one of CLU, with two large 
independently folded domains; the difference is that APOE is not cleaved and the two 
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halves are connected by a hinge region, rather than disulfide bonds. The N-terminal 
domain is an elongated four-helix bundle, while the C-terminal domain is highly α-
helical, but its structure is unknown. The α-helices that form this protein are highly 
amphipathic, making the protein stable both in lipid-bound and lipid-free 
conformation. Moreover, full-length APOE forms multimeric complexes in acqueous 
solution. Thr194 is the only glycosylated residue and its glycosylation is not 
necessary for APOE expression (Hauser et al., 2011). 
 Functionally, APOE can associate with lipids: in this case the conformation of 
the protein changes from the lipid-free form, a transition that is necessary for the high 
affinity binding of target proteins like the LDL receptor, the VLDL receptor, the LDL 
receptor related protein 1 (LRP1) and the APOE receptor. By binding these receptors, 
APOE-containing lipoproteins are cleared from the plasma, thereby regulating plasma 
cholesterol levels. These processes can be very important in brain, as a lack of 
cholesterol delivery causes synaptic and dendritic spine degeneration and results in 
failed neurotransmission and decreased synaptic plasticity. Moreover, APOE is 
involved in the clearance of cholesterol and lipid debris resulting from neuronal cell 
damage, cell death, traumatic brain injury or terminal differentiation. Finally, APOE 
is involved in the clearance of Amyloid-β protein in Alzheimer’s disease (Hauser et 
al., 2011, see also fig. 1.15). 
 ApoE is polymorphic and this influences its functional and structural 
properties. The three common allelic isoforms, apoE2, apoE3 and apoE4, differ at 
positions 112 and 158. ApoE3, the most common isoform, contains cysteine and 
arginine, respectively, whereas apoE2 has two cysteines and apoE4 has two arginines 
at these positions: these substitutions affect the position of some internal salt-bridges. 
ApoE3 and apoE4 bind to LDL receptors with similarly high affinity, but the binding 
of apoE2 is 50- to 100- times weaker. ApoE4, instead, is a major risk factor for 
Alzheimer’s disease, accounting for 40–60% of the genetic variability observed in the 
disease. Two key properties of apoE4 – domain interaction and reduced stability 
relative to apoE2 and apoE3 – have been suggested to underlie the association of 
apoE4 with this disease (Hatters et al., 2006). 
 
1.4.4 Tenascin R 
 Tenascin R (TNR) is a member of the Tenascin family, a group of four 
extracellular matrix glycoproteins, and is expressed exclusively in the nervous 
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system. TNR is highly conserved across the species, with 93% homology between the 
rat and human version. The protein structure (fig. 1.16) involves 4.5 epidermal growth 
factor-like (EGF) domains, 8 or 9 fibronectin type III repeats (FN III repeats), and a 
carboxyl-terminal region globular domain resembling the β and γ chains of fibrinogen 
(FG) (Carnemolla et al, 1996). TNR has two major molecular forms, TNR 160 (160 
kDa) and TNR 180 (180 kDa), probably generated by an alternative splicing on the 
exon coding for FN6. Isoforms possibly have a role in the formation of dimers and 
trimers. The relative amounts of the 180- and 160-kDa TNR isoforms change during 
CNS development. TNR undergoes extensive post-translational modification with 
sulfated oligosaccharides, both N-linked and O-linked, accounting for 10–20% of 
weight. The glycosylation pattern of TNR is developmentally regulated and affects its 
adhesion, motility and migration (Woodworth et al., 2004). 
 
 
Figure 1.16: Protein structure of Tenascin R. Red line: leader peptide; Green line: coiled coil region; 
EGF: EGF-like domain; FN3: Fibronectin type 3 domain; FBG: Fibrinogen-related domain. 
 
 
TNR interacts with proteins on the surface of both glial and neuronal cells, as 
well as with extracellular matrix proteins. Among the cell membrane associated 
ligands of TNR there are CNTN1 and voltage-gated Na+ channels; in the extracellular 
matrix proteins members of the lectican family of chondroitin sulfate proteoglycans 
(CSPGs) can be found, including aggrecan, versican, neurocan and, with highest 
affinity, brevican (Anlar and Gunel-Ozcan, 2012). 
 TNR has multiple, sometimes opposite roles: its versatility includes adhesive 
or antiadhesive, growth-promoting	   or inhibiting effects, depending on the type of 
targeted cells, receptors and signaling pathways, their location in the CNS, the 
composition of the surrounding ECM, and the time of interactions. EGF, FG, FN1–2 
and FN3–5 domains serve for anti-adhesive properties while FN6–8 domains mediate 
adhesive properties. TNR interaction with CNTN1 has a repulsive effect. Depending 
on the developmental context, instead, lecticans can collaborate with TNR or inhibit 
its action. In general, TNR is growth-promoting when constituting a uniform 
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substrate, and inhibiting when forming a sharp boundary of the substrate. TNR 
deficiency in vitro results in reduced oligodendrocyte differentiation and delayed 
myelin basic protein expression. On the other hand, overexpression results in reduced 
migration in embryonic stem cells, which travel shorter distances and differentiate 
more. TNR also induces the generation of GABAergic neurons (Anlar and Gunel-
Ozcan, 2012). 
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 Autism Spectrum Disorder (ASD) is a common and heterogeneous	  childhood 
neurodevelopmental disorder characterized by widespread abnormalities of social 
interactions and communication and a markedly restricted repertoire of repetitive self-
stimulatory behaviors.	   Learning disability (in about 70% of cases) and epilepsy (in 
about 30% of cases) are also frequently observed. Genetic studies on affected twins 
proved that, among cognitive diseases, ASDs are the most heritable (about 80%). 
Although several subtle but widespread abnormalities throughout the cortex 
have been found in autistic patients, recent findings suggest a potential unifying 
model in which higher-order association areas of the brain that normally connect to 
the frontal lobe are partially disconnected during development (Geschwind and Levitt 
2007). A key feature of ASDs is that they typically develop before two or three years 
of age, a time characterized by pruning of existing synapses and formation and 
maturation of new ones, suggesting that these can be some of the disrupted pathways 
that can lead to the brain disconnection. 
Several mutations associated to ASD have been found in CNTNAP2, whose 
encoded protein is Caspr2, a member of the NRXNs’ superfamily, as suggested by the 
primary sequence. This protein is primarily located at the juxtaparanodes of the 
myelinated neurons, where it favors the clustering of potassium channels Kv1 (Poliak 
et al., 1999). Two papers published in 2003 reported the direct binding of Caspr2 with 
CNTN2 (also known as TAG-1), a GPI-anchored protein expressed both by neurons 
and glial cells in the juxtaparanodal region (Poliak et al., 2003; Traka et al., 2003): the 
authors proposed that this association would help the accumulation of the Caspr2/Kv1 
complex in the correct localization. So far, little is know on the structure of the 
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Caspr2/TAG-1 complex. Moreover, Caspr2 has been proposed to have other 
localizations in the brain, such as the axon initial segment (AIS) of pyramidal cells, a 
portion that is devoid of myelin (Inda et al., 2006; Ogawa et al., 2008), and the 
synaptic terminals, even if it’s not clear if at the pre- or post- synaptic side 
(Bakkaloglu et al., 2008; Poliak et al., 1999; Zweier et al., 2009). 
A consistent observation emerging from recent studies is the discovery of 
mutations in the genes encoding NRXN1, NLGN3 and NLGN4 (Südhof, 2008). 
NLGNs and NRXNs families of proteins are synaptic cell-adhesion molecules that 
connect presynaptic and postsynaptic neurons, also modulating the maturation of the 
synapse and specifying its function. NRXNs are type I membrane proteins localized at 
the pre-synaptic button: there are three genes encoding for NRXNs in the human 
genome, each one encoding a longer α- and a shorter β-NRXN. Also NLGNs are type 
I membrane proteins: there are four genes encoding for NLGNs in the genome. 
Although all localized at the post-synaptic side, different NLGNs are present in 
different kinds of synapse: NLGN1 on the excitatory ones, NLGN2 on the inhibitory 
and NLGN3 and 4 on both. Sequence comparison indicates that NLGN1, NLGN3 and 
NLGN4 are more similar to each other than to NLGN2 (Südhof, 2008). Moreover, the 
binding affinity of NLGN2 for NRXNs is significantly lower than the other NLGNs 
(Comoletti et al., 2006). 
 
 This study is aimed at the research of novel binding partners for 
Caspr2 and NLGN2. Both these proteins have known binding partners, but it’s 
reasonable to think that they might have other ligands in the brain. In fact, Caspr2 has 
been found in the synapse, where there’s no clustering of K+ channels, possibly 
exerting an uncharacterized function. On the other hand, NLGN2 shows several 
differences from the other family members. The lower affinity for NRXNs and the 
lower sequence similarity to the other members of the family can reflect the presence 
of additional specialized functions for this protein in the inhibitory synapse that could 
be exerted through the association with an unidentified protein. The identification of 
new binding partners would give new insight in the molecular biology of these 
proteins and of the ASD pathology. For this purpose, fishing experiments were 
performed: these consisted of an affinity chromatography on the protein extract of a 
brain, using either Caspr2 or NLGN2 bound to the stationary phase and a mobile 
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phase, coupled with a mass spectrometry-based identification of the retained proteins. 
The identified proteins were then ranked on the probability to bind the target and the 
most promising were tested by means of co-immunoprecipitation (co-IP) and 
Isothermal Titration Calorimetry (ITC) experiments. 
 Another goal of this work is to better characterize the binding of 
Caspr2 with TAG-1. Since 2003, the year in which the direct association of these 
proteins was proposed, there hasn’t been any further in-depth analysis on this aspect; 
some preliminary experiments could open the way for further analysis on the structure 
of the complex. For this purpose, ITC experiments to measure the binding 
stoichiometry and affinity of the two proteins and co-IP experiments, using fractions 
of Caspr2 to map the region of binding, were performed. 
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3.1 MOLECULAR AND CELL BIOLOGY 
 
3.1.1 Eukaryotic Cell Culture 
 HEK-293 (Human Embryonic Kidney) cells were obtained from American 
Type Culture Collection (ATCC) and routinely grown as monolayers in Dulbecco’s 
modified Eagle’s medium (DMEM) with high glucose and 4mM L-Glutamine (Fisher 
Scientific) and supplemented with 10% FBS (Fisherbrand™ Research Grade Fetal 
Bovine Serum, Fisher Scientific). Cells were maintained in 10 cm dishes (Becton-
Dickinson) in a humidified incubator (Forma™ Steri-cycle™, Fisher Scientific), at a 
5% CO2 atmosphere. 
 To create stable selected lines, HEK-293 cells lacking the enzymatic activity 
of N-acetylglucosaminyltransferase-1 (Gnt1-) were used. For the clonal selection (see 
also par. 3.1.9), 800 µg/ml G418 (Geneticin, Sigma) was added to the HEK-293 
media. 
To produce high amounts of proteins, cells were grown in 3-layer flasks 
(Nunc™ TripleFlasks, Thermo Scientific) using DMEM supplemented with different 
amount of FBS (ranging from 10% to 0%) and with a 100X penicillin and 
streptomycin mix (HyClone™, Fisher Scientific). 
 
3.1.2 Bacterial culture 
 For the amplification of the plasmids (see also par. 3.1.3) E. coli DH5α strain 
[genotype: F- endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 
Δ(lacZYA-argF)U169, hsdR17(rK- mK+), λ–] was used. 
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 The bacteria were grown in Luria-Bertani medium (10 g/l tryptone, 5 g/l Yeast 
Extract, 10 g/l NaCl) to which the appropriate antibiotic was added as needed. The 
final concentrations used are: 
• Ampicillin: 100 µg / ml; 
• Kanamycin: 40 µg / ml; 
• Chloramphenicol: 20 µg / ml. 
 
To plate bacteria on solid media, 1.5 % Agar was added to the LB. The media 
were treated at 120°C for 20 minutes and then cooled down before adding the 
antibiotic. 
 
3.1.3 Plasmids used 
 The cDNAs encoding most of the proteins used in this work are cloned into a 
modified version of the pCMV6-XL4 vector. This was customized in Dr. Comoletti’s 
lab and has the following features (Fig. 3.1): 
• Optimized Kozac sequence, bearing the sequence gccRccATGG (where 
ATG is the first Met), recognized by the ribosome as the translational start 
site, for an enhanced translation efficiency; 
• A sequence encoding the Prolactin Leader Peptide (PLP), that is one of the 
most efficient translocation signals to direct the nascent protein through the 
Endoplasmic Reticulum (ER) and the Golgi to be either delivered to the 
plasma membrane or secreted (Hegde and Bernstein, 2006); 
• A sequence encoding the FLAG sequence DYKDDDDK placed between the 
PLP sequence and the Multiple Cloning Site (MCS); 
• Sequences encoding for a 3C protease cleavage site (LEVLFQ/GP) and for 
the Fc portion of the human IgG placed downstream the MCS. The IgG 
coding sequence contains introns that help stabilize the mRNA before 
translation. 
 
After cloning a cDNA in this vector, the produced protein would be secreted 
and would contain a FLAG tag at the N-terminal and a removable IgG tag at the C-
terminal. In some cases a former version of this plasmid that doesn’t have a FLAG 
sequence was used, producing a protein carrying only the IgG tag. 
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Figure 3.1: Scheme of the original pCMV-XL4 vector (top) and of the modified portion, after the 
cloning of a hypothetic cDNA between the sites NotI and XbaI (bottom). 
 
 
 Other than for the cloning of the cDNAs reported in par. 3.1.4 and 3.1.5, these 
vectors were used to express the following proteins: 
• Caspr2-1261*- IgG; 
• Caspr2-183*-IgG; 
• TAG-1-1004*- IgG; 
• FLAG- TAG-1-28-901- IgG; 
• FLAG- TAG-1-28-461- IgG; 
• FLAG- TAG-1-28-597- IgG; 
• FLAG- TAG-1-600-1027- IgG; 
• α-NRXN1-1309*-IgG; 
• FLAG-NLGN2-616*; 
• FLAG-NLGN1-639*- IgG; 
• FLAG-NLGN1-639*-G500A; 
• βNRXN1-300*- IgG; 
As a control, the vector encoding only the IgG was used: this has been called IgC that 
stands for “IgG Control”. 
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For the expression of the full-length membrane proteins instead the 
pCDNA3.1 vector was used. Those proteins were: 
• HA-Caspr2 wt; 
• FLAG-TAG-1 wt; 
• FLAG-NLGN1 wt 
• FLAG-NLGN2 wt 
As a control, an empty pCDNA3.1 vector was used. 
 
3.1.4 cDNAs 
 The cDNAs encoding for CNTN1, SFRP1, CLU, APOE and TNR were 
purchased from Open Biosystems (Thermo Scientific). Their sequences can be found 
in the GenBank database with the following accession numbers: 
• SFRP1: BC036503.1 
• CLU:  BC019588.2 
• APOE:  BC003557.1 
• CNTN1: BC066864.1 
• TNR:  BC129830.1 
 
The plasmids containing these cDNAs were extracted from the bacteria 
provided as described in par. 3.1.7. 
 
3.1.5 Cloning 
 Portions of the coding sequences of the cDNAs reported in par. 3.1.4 were 
cloned in the pCMV6-XL4-FLAG-IgG or pCMV6-XL4-IgG (par. 3.1.3), as reported 
in the results section. To achieve this goal, a PCR was used to insert a NotI site at the 
5’ end of the region of interest and an XbaI site at the 3’ end. The primers used were: 
SFRP1 è  FOR: AGTAAAGCGGCCGCAAGCGAGTACGACTACGT 
        REV: CGGCCTCGTCTAGACCCTTAAACTCGGACTGAAAGG 
CLU è FOR: AGTAAAGCGGCCGCAGACCAGACGGTCTCAGA 
  REV: CGGCCTCGTCTAGACCCTCCTCCCGGTGCTTT 
APOE è FOR: AGTAAAGCGGCCGCAAAGGTGGAGCAAGCGGT 
  REV: CGGCCTCGTCTAGATGATTGTCGCTGGGCACA 
 
Section 3  Materials and Methods 	  	  
	   46 
CNTN1 è  FOR: AGTAAAGCGGCCGCAGACTTTACCTGGCACAG 
         REV: CGGCCTCGTCTAGACCGAATTCCGAGTAGACAAGA 
TNR è FOR: AGTAAAGCGGCCGCAGGCCAGACCTCAGAC 
  REV: CGGCCTCGTCTAGACCGAACTGTAAGGACTGCC 
 
The PCR reactions were conducted in a final volume of 50 µl using the above 
mentioned primers and the phusion high-fidelity DNA polymerase (New England 
Biolabs): 
• 10 µl of reaction buffer (5x); 
• 1.2 µl of forward primers (5 µM); 
• 1.2 µl of reverse primers (5 µM); 
• 1.5 µl of dNTPs (10 mM each); 
• 1 µl of template DNA (5 ng/µl); 
• 34.6 of µl H2O; 
• 0.5 µl of High fidelity TAQ polymerase; 
 
Table 3.1: Thermo cycle used for the cloning PCR 
 
 
The amplified DNA and the vector were digested at 37°C for 1 hour, using 
NotI and XbaI restriction enzyme (New England Biolabs) in a final volume of 20 µl.  
 
Cloning PCR cycle 
Step Temperature (°C) Incubation time Cycles 
Initial denaturation 98 2 min 1 
Denaturation  98 20 sec 
2 Annealing 50 30 sec 
Elongation 72 30 sec per Kbp 
Denaturation  98 20 sec 
25 Annealing 65 30 sec 
Elongation 72 30 sec per Kbp 
Final elongation 72 10 min 1 
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For each reaction:  
• DNA è 1 µl for the vector, 10 µl for the PCR-amplified DNA (insert); 
• 2 µl of NEbuffer 3.1 (10x); 
• 1 µl of NotI enzyme; 
• 1 µl of XbaI enzyme; 
• H2O up to 20 µl. 
 
The digested DNAs were purified from a 1% agarose gel, using a 
NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel) according to the 
manufacturer protocol. The purified DNAs were quantified on a 1% agarose gel and 
ligated using a T4 DNA ligase (New England Biolabs) in a final volume of 20 µl, 
incubating 30 minutes at room temperature and over-night at 4°C: 
• DNA è 3:1 molar ratio insert:vector; 
• 2 µl of T4 buffer (10x); 
• 1 µl of T4 DNA ligase; 
• H2O up to 20 µl. 
 
Chemically competent DH5α bacteria were transformed with 2 µl of ligation 
product (protocol described in par. 3.1.6). 
 
3.1.6 Bacterial transformation 
 Chemically competent cells were prepared in the Comoletti laboratory and 
conserved at -80°C. Bacterial transformation was performed through a heat shock at 
42°C for 45 seconds. The protocols used were described by Seidman et al. in “Current 
Protocols in Molecular Biology” (1997). 
 
3.1.7 Plasmid DNA purification 
 The purification of plasmidic DNA was carried out using NucleoSpin® 
Plasmid Mini-prep kit (Macherey-Nagel) or with NucleoBond® Xtra Maxi-prep kit 
(Macherey-Nagel), according to the manufacturer protocol. The concentration of the 
purified DNA was tested using a Nano drop 2000c (Thermo Scientific).  
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3.1.8 HEK cells’ transfection 
 70% confluent HEK cells were transfected with the calcium phosphate method 
as described by Kingston et al. in “Current Protocols in Molecular Biology” (1996), 
using 10 µg of each plasmidic DNA.  
 
3.1.9 Selection of stable transfected cells 
 In order to achieve protein purification, HEK293 Gnt1- cells were transfected 
with a pCMV6-XL4 vector encoding the selected protein (see also par. 3.1.3, 3.1.4, 
3.1.5 and 3.1.8). The cells were also transfected with 3 µg of a pCDNA3.1 carrying 
the geneticin resistance gene (neo: aminoglycoside 3'-phosphotransferase). The cells 
were then selected by growth in 800 µg/ml G418-added media (see also par. 3.1.1). 
After ~20 days the cells usually form colony-like spots each representing a single 
clone. The clones were then selected and grown in a 24-well plate. After ~3-4 days 
the medium of each clone was tested by western blot (see also par. 3.2.1) to verify the 
level of expression of the protein. The clones with the higher level of expression were 
expanded on 10 cm plates. 
 
3.1.10 Protein extraction from HEK cells 
 To collect the protein content of HEK cells the following protocol was used. 
The cells were harvested and centrifuged at 1200 g for 5 minutes. The pellet was 
resuspended in 1 ml of lysis buffer (150 mM NaCl + 50 mM Tris-HCl pH 8 + 1% 
triton X100) to which leupeptin 1µM (Sigma) was added. After 20 minutes of 
incubation on ice, the samples were centrifuged at max speed for 10 minutes and the 
supernatant was collected. 
 
3.1.11 Protein purification 
 In this work several proteins were purified. These are naturally secreted 
proteins, GPI anchored proteins or single-pass trans-membrane proteins. In the last 
two cases the attention has been focused on the extracellular portion and, for this 
reason, the gene encoding the protein was cloned till few residues before the anchored 
residues or the trans-membrane domain. Therefore, the proteins to be purified were all 
released by the cells in which they were produced. 
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 Stably transfected HEK 293 Gnt1- cells (see also par. 3.1.9) were cultured in a 
3-layer flask (see also par. 3.1.1). In the DMEM media used, a 100X pen-strep mix 
and different concentrations of FBS were added. The concentration of FBS used were: 
• 10% to plate the cells and for the first 4 days; 
• 5% for the following 2 days; 
• 2% till when the desired amount of media was collected, replacing it every 
day. 
The 2% FBS concentration was chosen to allow cell survival while reducing the 
amount of unwanted serum proteins that can lower the protein yield in the purification 
steps.   
The media collected from the flasks was spun down to eliminate any detached 
cell and then a protease inhibitor cocktail (Benzamidine 4%, Bacitracine 1%, Na 
Azide 2%, EGTA 100 mM) was added for storage till the purification step. 
 
The buffers used for the purification were: 
TNE:    50 mM Tris-HCl pH 8.0 + 
150 mM NaCl   + 
1 mM EDTA 
 
TNED:   TNE    + 
1 mM DTT 
 
Washing buffer: TNE    + 
450 mM NaCl 
 
HBS:   20 mM HEPES  + 
   150 mM NaCl 
 
The collected media was passed through a chromatography column by gravity 
flow to purify the protein of interest. In the column a protein-A-coupled resin (Captiv-
A PriMab affinity resin by RepliGen) was placed to allow the binding of the IgG-
fused protein. Once all the media was passed through the column, the resin was 
washed 3 times with washing buffer, to remove any residual media, equilibrated with 
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TNE and then TNED. The reaction with 10 µg/ml of 3Cpro-GST fusion enzyme was 
carried-on over-night at 4°C in 1 resin volume of TNED added of leupeptin 1 µM. 
After the elution of the protein with 6 volumes of HBS, the resin was regenerated 
incubating it in a solution containing 50mM Gly pH2.0 and 500mM NaCl for 10 
minutes and then washing 3 times with about 20 ml of washing buffer. The flow-
through of the first round of purification was loaded again to enhance the yield of the 
purification. The eluted mix was incubated for 1 hour at 4°C on a lab roller with 0.1 
ml of protein-A resin and 50 µl of a Glutathione (GSH) Sepharose resin (GE 
healthcare) and then spun to remove possible uncleaved proteins and the 3C pro 
enzyme. The purified protein, contained in the supernatant, was concentrated in an 
appropriate sized “vivaspin 6” column (Sartorius stedim biotech), quantified using a 
Nano drop 2000c (Thermo Scientific) and checked for purity, aggregation and 
degradation by size exclusion chromatography (SEC) (see also par. 3.1.12) and SDS-
PAGE stained with Coomassie (see also par. 3.2.1). 
 
3.1.12 Size exclusion chromatography 
Size exclusion chromatography (SEC) experiments were used to assess purity, 
aggregation and degradation of purified protein, as well as for checking the binding 
properties of two injected proteins. The experiments were performed using an AKTA 
instrument (GE Healthcare) with a constant flow speed of 0.5 ml/min, using a buffer 
containing Hepes 10mM pH 7.4 and NaCl 150 mM. 200 µl of protein were loaded for 





3.2.1 SDS-PAGE and Western Blot 
 Coomassie stained SDS-PAGE and Western blot analysis were used for 
several purposes during this study, like the evaluation of purified proteins (par. 
3.1.11), the estimation of the level of expression of stable transfected cells (par. 3.1.9) 
and the detection of protein pulled down trough co-immunoprecipitation (par. 3.2.2). 
 The protein samples were added with 4x	   SDS-PAGE loading buffer and 
boiled for 5 minutes at 100°C. They were then loaded on a 10%	  SDS polyacrylamide 
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precast gel (Bio-Rad) and run in a SDS-PAGE apparatus (Bio-Rad) at 200 V for 35 
minutes. 
At the end, the proteins were either stained with Coomassie Brilliant Blue R-
250 (Bio-Rad) for 1 hour or transferred on a nitrocellulose membrane in a transfer 
apparatus (Bio-Rad) at 100 V for 45 minutes for immuno-blotting. 
 
The membrane was blotted with the following protocol: 
• 1 hour incubation in 5% milk; 
• 1 hour incubation in a solution of 1% milk in which a specific antibody was 
added; 
• 3 washes in PBS; 
• 1 hour incubation in a solution of 1% milk in which a secondary antibody 
conjugated with horseradish peroxidase (HRP) was added; 
• 3 washes in PBS; 
• addition of the HRP substrate (HyGLO™ Chemiluminescent HRP Antibody 
Detection Reagent, Denville Scientific) 
• exposure of an autoradiography film (HyBlot CL, Denville scientific Inc.) and 
development in a KODAK MIN-R film processor. 
 
The following antibodies (Ab) were used, at the final concentration suggested by the 
manufacturer: 
• Peroxidase-conjugated AffiniPure Goat Anti-Human IgG (Jackson Immuno 
Resarch, USA); 
• Monoclonal mouse Anti-FLAG (Sigma); 
• Monoclonal mouse Anti-HA (Fisher Scientific); 
• Goat anti-mouse IgG-HRP (Santa Cruz Biotechnology); 
• Goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology). 
Note: when using the anti-human IgG to blot proteins fused with the human-fc, no 
primary Ab is needed. 
 
3.2.2 Co-immunoprecipitation experiments 
 In order to evaluate protein binding, co-immunoprecipitation (co-IP) 
experiments were performed. HEK cells were transiently transfected, as described in 
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par. 3.1.8. Depending on the goal of the experiment, either one plate of cells was co-
transfected with the plasmids encoding the proteins to be tested or two different plates 
were independently transfected with one of them and then the cell lysates (or the 
culture media) were mixed.  
• Co-IP on cell lysate: the protein content of the cells was collected as in par.  
3.1.10. The samples were then incubated with 40 µl of a protein-A-coupled 
resin (Captiv-A PriMab affinity resin by RepliGen) or an anti-FLAG resin 
(Sigma) and placed on a lab roller for 1 hour. At the end they were spun 30 
seconds on a microcentrifuge and the pellet was washed 3 times with lysis 
buffer. 20 µl of 2x	  SDS-PAGE loading buffer was added and the samples were 
boiled for 5 minutes at 100°C and analyzed through western blotting (par. 
3.2.1).  
• Co-IP on culture media: the culture medium of the cells was collected and 
centrifuged at 1200 g for 5 minutes to remove residual cells. The samples 
were then incubated with 40 µl of a protein-A-coupled resin (Captiv-A PriMab 
affinity resin by RepliGen) or an anti-FLAG resin (Sigma) and placed on a lab 
roller for 1 hour. At the end they were spun 30 seconds on a microcentrifuge 
and the pellet was washed 3 times with PBS (Fisher). 20 µl of 2x SDS-PAGE 
loading buffer was added and the samples were boiled for 5 minutes at 100°C 





3.3.1 Fishing experiments 
 To identify new candidate binding partners for Caspr2 and NLGN2, fishing 
experiments were performed on three different brain samples. 
• Human adult brain (2 grams of frontal cortex bought from a tissue bank); 
• Human embryonic brain (2 grams of frontal cortex bought from a tissue bank); 
• Rat adult brain. 
 
These experiments were performed as represented in fig. 4.9 (pag. 70). For 
each brain sample, the extracted proteins were pre-cleared with an IgC-bound resin to 
filter out all the proteins that would non-specifically bind to the resin or to the human 
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IgG portion that is used to link the resin to the bait molecule (i.e. Caspr2, NLGN2, 
etc.). The unbound portion was then incubated with a Caspr2-bound resin and then 
split in 3 parts and incubated with α-NRXN1-, NLGN1- or NLGN2-bound resin. This 
order was chosen to both give the priority to the identification of Caspr2 ligands and 
avoid the progressive depletion of the protein pool after each step. 
 
The buffers used were: 
- Buffer A: 20 mM Hepes pH 7.4  + 
  150 mM NaCl  + 
  1,2% triton X100 
 
- Buffer B: Buffer A  + 
  4 mM CaCl2   +  
  4 mM MgCl2 
  
The resins used were prepared incubating 750 µl of a protein-A-coupled resin 
(Captiv-A PriMab affinity resin by RepliGen) with a saturating amount of the 
following purified proteins (see also par. 3.1.3 and 3.1.11) for 1 hour at 4°C on a lab 
roller: 
• IgC, intended as the control IgG, corresponding to only the fc portion fused 






Each brain sample was homogenized in about 70 ml of buffer A. The volume 
was then adjusted to 210 ml (105 ml buffer A + 105 ml buffer B). The lysates were 
incubated for 2 hours at 4°C on a lab roller and then for 30 minutes at 37°C. To 
precipitate the cellular debris and collect the proteins, the lysate was centrifuged 3 
times, collecting at each step the supernatant, as follows: 
• 10000 g, 20 min, 4°C; 
• 16000 g, 20 min, 4°C; 
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• 16000 g, 20 min, 4°C; 
 
The clarified lysate was incubated with 750 µl of the IgC-bound resin and 
incubated for 1 hour at 4°C on a lab roller. The mix was then poured in a column 
(Borosilicate Glass Economy Chromatography Columns, Kimble Chase) and the 
flow-through was collected. The resin was collected in 750 µl of buffer B for the 
washing and elution step (see below). 
The flow-through was incubated with 750 µl of the Caspr2-bound resin for 1 
hour at 4°C on a lab roller. The flow-through and the resins were collected as before. 
This flow-through was split in 3 equal amounts and each was incubated with 
250 µl of the α-NRXN1-, NLGN1- or NLGN2-bound resin for 1 hour at 4°C on a lab 
roller. The resin was collected as before, while the flow-through was discarded. 
All the collected resins were washed in 2 volumes of buffer B and eluted by 
boiling at 100°C for 5 minutes. At this point the proteins were precipitated by 
incubating for 10 minutes in 4 volumes of Trichloroacetic acid (TCA) and 
centrifuging 4 minutes at max speed. The protein pellet was then washed two times in 
cold acetone and dried at 95°C for 10 minutes. The proteins collected were then 
analyzed by Mass Spectrometry at the Biomolecular/Proteomics Mass Spectrometry 





3.4.1 Isothermal Titration Calorimetry 
 To study the binding proprieties of two purified proteins, ITC experiments 
using Microcal iTC200 (GE Healthcare) were performed, using Hepes buffer with 
Ca2+. The scheme presented in fig. 3.2 shows the principle of this technique. A 
protein is titrated into a solution of its binding partner. The instrument measures the 
binding enthalpy change due to the interaction by detecting the heat exchange in the 
chamber: this is calculated by the instrument through the power that it applies to the 
sample cell to keep the temperature difference with a reference cell constant. Several 
injections of the titrant are performed and the heat exchange is recorded after each 
one: in case of association the signal diminishes as the system reaches saturation, until 
the only heat exchange is due to the dilution of the protein and background noise are 
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observed. A graph recording the µcal/sec exchanged over time is reported as results; a 
binding curve is then obtained from a plot of the integral of each heat exchange peak 
from each injection against the ratio of ligand and binding partner in the cell. The 
binding curve is analyzed with the appropriate binding model to determine Kd, 
stoichiometry (N), ΔH and ΔS (see also fig. 4.1 for some examples). 
The samples used for ITC experiments need to be in matching buffers and the 
two proteins have to be pure to avoid non-specific signals. As a control, a separate 
experiment injecting the titrant protein in a chamber containing only buffer is 
performed and the values are subtracted from the previous one, to correct the signal 






















4.1 CHARACTERIZATION OF THE BINDING BETWEEN 
CASPR2 AND TAG-1 
 
 Since when the association of Caspr2 and TAG-1 was proposed in 2003, 
research has been focused on its physiological role in myelinated neurons, trying to 
explain the association of this complex with several diseases, such as ASD, Epilepsy, 
Gilles de la Tourette syndrome, etc. Little attention has been given instead to the 
characterization of the binding proprieties of the complex. All the available data come 
from pull-down experiments performed on rat brain and on cell lysates from HEK co-
transfected with the two exogenous proteins. Multiple questions remain thus 
unsolved, as, for example, what the affinity and the stoichiometry of the complex are 
and which domains and which residues it involves. 
 
4.1.1 Biophysical analysis of the complex 
 For a first characterization of the binding properties of Caspr2 and TAG-1, an 
Isothermal Titration Calorimetry (ITC) experiment was performed. This technique 
uses purified soluble proteins to calculate the binding affinity of a complex. It has the 
advantage that the association can happen in solution, removing potential artifacts, 
such as binding site unavailability in immobilization-based techniques. Since Caspr2 
has a trans-membrane hydrophobic domain, it is not suitable for an experiment 
performed in an aqueous buffer. In any case, what emerges from the available 
information on the two molecules is that, with TAG-1 being a GPI-anchored protein, 
the binding should take place between the extracellular portions of the proteins. It is 
therefore possible to focus on these soluble parts. 
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The ITC system uses the concept that the binding process involves a certain 
amount of energy exchange with the environment; by measuring that heat exchange 
we can have an indication of the association potential. Two interacting molecules will 
show decreasing heat exchange values after each injection of one of them, used as a 
titrant, in a solution containing its binding partner, reflecting the progressive 
occupation of all the protein binding sites, resulting then in a curve sigmoidal and 
asymptotic to the zero line; non interacting proteins, instead, won’t show any heat 
exchange, if not the one due to the dilution of the titrant, resulting in a flat curve 
centered on the zero line. By measuring the extent of the energy exchanged and the 
concentration of the proteins, the parameters of the binding, such as Kd and 
stoichiometry, can also be calculated. 
 In fig. 4.1A the results of the ITC experiments are reported. The purified 
proteins used are Caspr2-1261* and TAG-1-1004*, corresponding to their entire 
extracellular domains. Surprisingly, no binding was detected. As a control, an ITC 
experiment was performed using the proteins NLGN1-639* and βNRXN1-300*. As 
for Caspr2 these two proteins have a trans-membrane hydrophobic domain, so only 
the extracellular soluble domains were purified and used for this binding experiment. 
Moreover, these two proteins are well known to interact: for the NLGN1-639* / 
βNRXN1-300* association, Comoletti and colleagues (2006) reported 30 nM by SPR; 
Araç and colleagues (2007), instead, reported 97 nM, and Chen and colleagues (2008) 
also reported 93 nM, both by ITC. This couple of proteins represents thus a good 
positive control. As shown in fig. 4.1B, the results of this experiment reported an 
excellent binding curve with a Kd of 116 nM and a stoichiometry very close to 1, 
proving the reliability of this system. 
 Because these results were not consistent with the generally accepted idea that 
Caspr2 and TAG-1 directly bind in vivo, it was necessary to perform other 
experiments using a different approach, in order to gain more insights into this 
controversial aspect. For this reason, a size exclusion chromatography experiment 
was performed. This technique gives the possibility to separate proteins on the basis 
of their molecular weight and shape. The peak profile of the two proteins injected 
after one hour of co-incubation would reflect their actual binding abilities: in the case 
that a tight complex is formed, it would be eluted faster than the two proteins injected 
alone and an additional peak, shifted to a lower elution volume, would appear; 
instead,  in  the case that  no  association  resulted  from  the incubation,  no peak shift  
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Figure 4.1: Results for the ITC analysis using the proteins Caspr2-1261*, used as titrant at a 
concentration of 61 µM, and TAG-1-1004*, used at the concentration of 6 µM (A), or βNRXN1-300*, 
used as titrant at the concentration of 100 µM, and NLGN1-639*, used at the concentration of 10 µM 
(B). In case of association the calculated values for Kd and stoichiometric ratio (N) of the interaction 





Figure 4.2: (A) Size exclusion chromatography results of Caspr2 (red line) and TAG-1 (green line) 
injected alone and of the two proteins injected together (blue line). (B) SDS-PAGE analysis of the 
purified Caspr2 and TAG-1 proteins. 
A B 
A B 
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would be observed. As seen in fig. 4.2A, no differences can be noted in the elution 
peak profiles when the proteins are injected together (blue line) in comparison to the 
independent injection of Caspr2 (red line) and TAG-1 (green line), while the relative 
height of the peaks is also conserved. Moreover, the analysis of the two purified 
proteins by means of Coomassie blue staining, reported in fig. 4.2B, showed two 
single bands at the expected molecular weight for Caspr2 and TAG-1: together with 
the symmetry of their corresponding peaks in the chromatogram, this proves that the 
proteins used in these experiments were pure, monodispersed, and not degraded. All 
together, these results are consistent with the ITC analysis previously shown, 
providing strong evidence that when these two proteins are put together in an aqueous 
medium in vitro, they don’t interact. 
 
4.1.2 Co-immunoprecipitations using full-length and truncated proteins 
 The ITC and chromatography experiments, performed using the purified 
extracellular portion of Caspr2 and TAG-1, failed to confirm the association between 
these two proteins. Even though they provided strong data proposing the idea that the 
two molecules do not actually interact, these experiments had the limitation of being 
performed in vitro. It was, therefore, interesting to replicate the binding data 
published in 2003 (Poliak et al., 2003, Traka et al., 2003, see also fig. 1.7 and 1.8), 
whose authors instead used an ex-vivo approach. For this purpose, the same co-
immunoprecipitation (co-IP) experiments proposed in those articles were performed. 
These consisted of the use of two different protocols: 
1. Co-transfection: HEK-293 cells were transfected with both the plasmid 
encoding HA-Caspr2 wt and the one encoding FLAG-TAG-1 wt and then the 
cell lysate was used for immunoprecipitation, using anti-FLAG antibodies; 
2. Independent transfection: two different plates of HEK-293 cells were 
transfected with either of the two plasmids independently. The two cell 
lysates were then mixed together and used for immunoprecipitation, using 
anti-FLAG antibodies. 
In both cases an experiment using Caspr2 and an empty vector was performed as a 
control. 
Both Poliak and Traka reported that the interaction happens only when the 
proteins are co-expressed, proposing that this was due to the need for the two proteins 
to associate in “cis” on the same cell surface membrane. Consistent with those results, 
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the western blot analysis shown in the top panel of fig. 4.3, reveals that, using the co-
transfection protocol, the precipitation of TAG-1 pulls-down also Caspr2, while the 
mock experiment result was negative. On the contrary, when transfecting the two 
plasmids independently, the Caspr2 band was not visible after the FLAG 
immunoprecipitation (fig. 4.3, bottom panel). Thus, our experiments replicated the 




                	  
 
Figure 4.3: HEK-293 cells were co-transfected (A) or independently transfected (B) with plasmids 
encoding HA-Caspr2 wt or FLAG-TAG-1 wt. The final lysates (that in the case of independent 
transfection result from the mix of two different lysates) were incubated with anti-FLAG antibodies for 
the immunoprecipitation of TAG-1. As negative control, an empty pCDNA3.1 vector, coding only for 
the FLAG peptide (Mock), was used in place of TAG-1. The precipitated proteins were evaluated by 
western blotting using anti-HA antibodies. 
 
 
The need of the Caspr2-TAG-1 complex to be formed during protein 
maturation and delivery to the cell membrane would explain the negative results	  
obtained using purified proteins in vitro, but if this is the case more evidence should 
A 
B 
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be provided to test this hypothesis. For example, the same model has been proposed 
for the interaction of the proteins Caspr1 and CNTN1: the binding happens in the ER 
and the complex is delivered already formed to the cell membrane. However, the 
transport of Caspr1 to the surface is dependent on CNTN1, since when expressed 
alone in CHO cells, Caspr1 is retained in the ER (Faivre-Sarrailh et al., 2000). This, 
instead, doesn’t happen to Caspr2 that is trafficked to the cell membrane even when 
expressed independently of TAG-1 (Falivelli et al., 2012). 
 To prove if effectively Caspr2 needs to bind TAG-1 in the ER in order to form 
a complex, the extracellular domains alone can be used. By co-expressing HA-
Caspr2-1261* and FLAG-TAG-1-1004*, the complex would in theory be secreted 
and it could be pulled-down from both the culture media and the cell lysate. In fig. 4.4 
the results are reported: as expected, after the immunoprecipitation of TAG-1 in the 
lysate, the band corresponding to Caspr2 is visible in western blotting. However, the 
same is not true when TAG-1 is pulled down in the media, indicating that the 
complex of the truncated forms is not secreted. As a control, TAG-1 was correctly 
secreted and pulled down, both in lysates and in media. 
 
 
	  	  	  	  	  	  	   	  
 
Figure 4.4: HEK-293 cells were co-transfected with plasmids encoding HA-Caspr2-1261* or FLAG-
TAG-1-901*. Both cell lysates and culture medium were incubated with anti-FLAG antibodies for the 
immunoprecipitation of TAG-1. The precipitated proteins were evaluated by western blotting using 
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Figure 4.5: (A) Schematic representation of the truncated fragments of TAG-1 used in co-IP 
experiments.  Ig: Immunoglobulin domains; FN3: Fibronectin like domains. (B-C) Results of the co-IP 
experiments using truncated versions of TAG-1. HEK-cells were co-transfected or independently 
transfected with plasmids encoding HA-Caspr2 wt or the FLAG-tagged fragments of TAG-1 above 
reported. The final lysates (that in the case of independent transfection result from the mix of two 
different lysates) were incubated with anti-FLAG antibodies for the immunoprecipitation of TAG-1. 
The precipitated proteins were evaluated by western blotting using anti-HA antibodies to detect Caspr2 
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 Moreover, in order to get further insight, the characterization of the putative 
binding site conveyed interesting information. Co-IP experiments were performed 
using truncated versions of TAG-1. The fragments tested are reported in fig. 4.5A and 
consist of: 
• Immunoglobulin (Ig) domains 1-4 (aa 28-461), 
• Ig domains 1-6 (aa 28-597); 
• Fibronectin (FN) like domains 1-4 (aa 600-1027). 
• Full-length TAG-1. 
 
The experiments were carried out with both the co-transfection and the 
independent-transfection protocols, using also HA-Caspr2 wt. If in the neuron binding 
between Caspr2 and TAG-1 and between the latter and another TAG-1 molecule 
expressed from the glial cells occurs, it is expected that these two events would 
require different surfaces: therefore only one of the fragment used would give a 
positive result. Unexpectedly, the results, reported in fig. 4.5B, showed that, using the 
co-transfection protocol, a positive band is visible for each of the truncated forms of 
TAG-1 tested, even when they don’t share any overlapping regions. Moreover, the 
intensities of the bands are similar between them and to the full-length protein. As 
expected, using the independent-transfection protocol, no band is visible, even if all 
the truncated TAG-1 proteins were correctly expressed and pulled-down (fig. 4.5C). 
 Altogether, the information provided by these results seems conflicting: on 
one hand, the complex can be pulled down only in cell lysates and only after the co-
expression of the two proteins; on the other hand, the extracellular domains fail to 
bind when tested by means of both ITC and co-IP. Moreover, non-overlapping 
portions of TAG-1 can pull down Caspr2. Even if it cannot be excluded that the 
binding region of the two proteins involves different domains, at least a reduced 
affinity would be expected when using only a portion of TAG-1: an artifact in the set-
up of the co-IP experiment has thus to be taken in account. 
 
4.1.3 Validation of the co-IP protocol 
 Due to the conflicts among the data presented above, the reliability of the used 
co-IP protocol had to be tested. For this purpose, both positive and negative controls 
were needed. 
Section 4  Results 	  
	   64 
	  	  
Figure	  4.6: HEK-293 cells were co-transfected with plasmids encoding either the couple of proteins 
FLAG-NLGN1-639* and βNRXN1-300*-IgG or the couple of proteins FLAG-NLGN1-639*-G500A 
and βNRXN1-300*-IgG. Both cell lysates and culture medium of each plate were incubated with a 
protein-A coupled resin for the immunoprecipitation of βNRXN1. The precipitated proteins were 
evaluated by western blotting using anti-FLAG antibodies.	  
 
  
Because no protein, other than TAG-1, has been proposed to directly bind 
Caspr2, the proteins FLAG-NLGN1-639* and βNRXN1-300*-IgG were used as a 
positive control. These proteins were already used for the same purpose in the ITC 
experiments, due to their high affinity interaction. Moreover, in 2010 Leone and 
colleagues proved that the mutation of the glycine in position 500 to an alanine could 
abolish the binding propriety of NLGN1 to its counterpart: therefore, the G500A 
mutant was used as a good negative control for these experiments. All these proteins 
are truncated forms, corresponding to the extracellular portion that is known to be 
responsible for the NLGN-NRXN binding (see par. 1.3.3): thus the complex is 
expected to be precipitated from the cell lysate as well as the media. The co-IP was 
performed with the same protocols used for the secreted Caspr2 and TAG-1 (fig. 4.4), 
pulling down βNRXN1 through a protein-A coupled resin that binds its IgG tag. The 
results are presented in fig. 4.6. As expected NLGN1 wt was co-precipitated both in 
the media and in the cell lysate. The interesting results come instead from the G500A 
mutant: as expected, whereas in the media almost no protein was detected, in the cell 
lysate a band similar in intensity to the wt could be found. Altogether this proves that 
it is possible to pull-down a secreted complex from the culture media, after the co-
expression of the proteins from the same cell, proving how the failure in the co-
precipitation of the Caspr2-TAG-1 complex was effectively due to a lack of binding 
or a low affinity of the putative complex and not to an experimental issue. At the 
Section 4  Results 	  
	   65 
same time, the co-expression of two glycoproteins leads to the generation of artifacts 
when the binding ability is evaluated in the cell lysates. 
To better analyze this potential to generate artifacts of the proposed co-IP 
protocol, several proteins that are not supposed to bind Caspr2 were tested. These are: 
1. Caspr2 domain 1 (aa. 1-183): Caspr2 does not dimerize (Comoletti 
unpublished data). Moreover, this represents only one domain of the 
extracellular portion of the protein (Discoidin domain, fig 1.3); 
2. CNTN1 (aa 21-986): this protein that belongs to the same family of TAG-1 is 
supposed to bind Caspr1, but not Caspr2 (Poliak et al., 2003). Also this protein 
is GPI anchored and for these experiments it was truncated to be released; 
3. Clusterin (CLU), also known as APOJ (full length): no association has ever 
been reported between these two proteins. Moreover, fishing data (see par. 
4.2.1) does not predict any binding. CLU is a naturally secreted protein, 
cleaved in two halves that remain associated through disulfide bonds (De Silva 
et al., 1990). 
 
All the proteins were expressed fused to both a FLAG at the N-terminal and an 
IgG tag at the C-terminal. The plasmids encoding these proteins and Caspr2-1261* 
were either co-transfected or independently transfected in HEK cells as already done 
for the extracellular domains of Caspr2 and TAG-1. The pull-down of the IgG fused 
protein, using a protein-A coupled resin, resulted in the co-precipitation of Caspr2 in 
all the cases (fig. 4.7A, top panel). On the contrary, when the proteins were 
independently expressed and the cell lysates mixed together no Caspr2 band could be 
detected (fig. 4.7A, bottom panel), even if all the proteins were correctly expressed 
and pulled-down (fig. 4.7B). 
The results just presented are consistent with those emerging from the use of 
NLGN1 wt and NLGN1 G500A. Anyhow, when comparing these experiments to 
those reported in fig. 4.3 for the couple Caspr2-TAG-1, it has to be taken in account 
that even if the protocols used are the same and the results should be comparable, 
these last two experiments were performed using different tags for the precipitation. 
In fact, while TAG-1 was fused to a FLAG peptide, these proteins carry a human IgG-
fc tag. It is possible that this additional peptide could bridge a non-specific association 
when it co-localizes with Caspr2  in the ER. To verify that this is not the case,  a co-IP  
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Figure	  4.7:	  HEK-cells were co-transfected or independently transfected with plasmids encoding HA-
Caspr2 wt or one protein among FLAG-Caspr2-183*-IgG, FLAG-CNTN1-986*-IgG and FLAG-CLU-
wt-IgG. The final lysates (that in the case of independent transfection result from the mix of two 
different lysates) were incubated with a protein-A coupled resin for the immunoprecipitation of the 
tested protein. The precipitated proteins were evaluated by western blotting using anti-HA antibodies 
(A) to detect Caspr2 or anti-human IgG antibodies (B) to prove the correct precipitation of the pulled-
down proteins for the independent transfection. 
A 
B 
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experiment was performed using HA-Caspr2 co-expressed with the IgG peptide alone 
(IgC) or a TAG-1-IgG fusion protein. Moreover, 1 ml of FBS was added during the 
precipitation phase of the mock experiment to check if one of the proteins present in 
the serum, that is always present in the culture of the cells, can interfere with the 
experiments. As shown in fig. 4.8, only TAG-1 can pull-down Caspr2, proving that 
these variables are not responsible of the positive bands previously shown. 
Altogether the results presented show that the co-transfection protocol for co-
IP presented above can’t be used when the association of the two glycoproteins is 
evaluated in the cell lysates, because false-positive artifacts can be generated: in fact, 
every tested protein can be precipitated using this protocol, regardless of the actual 
binding affinity. The most likely and simple explanation of this phenomenon is that a 
cellular protein bridges the contact between the two proteins during their maturation, 
but is no longer bound when they are delivered to the cell membrane. Unpublished 
data from Comoletti lab proved that one of the proteins that exerts this function is 
Calnexin, a resident chaperone of the Endoplasmic Reticulum (ER). This flaw could 
have affected the original experiments conducted in 2003, in which over-expressing 
the two proteins in the same cell, the authors observed a direct association between 
Caspr2 and TAG-1 (Poliak et al., 2003; Traka et al., 2003; see also fig. 1.9 for the 
proposed model). The results reported here also show no direct binding for this couple 
of proteins. However, no information is provided on whether or not the two proteins 
belong to the same macromolecular complex bridged by a third protein. The 
experiments proving this kind of association were conducted on rat brain’s lysates by 
the same authors: false positive artifacts due to the post-translational binding to ER 
resident chaperones would affect more likely experiments performed with proteins 
that were over-expressed rather than those performed on brain lysate’s sample. 
Moreover, strong evidence comes from co-localization data published on the same 
papers. It is therefore likely that Caspr2 and TAG-1 associate indirectly, but further 
experiments are needed. This evidence, together with the fact that TAG-1 was the 
only proposed ligand of the extracellular portion of Caspr2, makes very interesting the 
characterization of new potential partners for this protein. 	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Figure 4.8: HEK-cells were transfected with a plasmid encoding HA-Caspr2 wt. To address if the IgG 
protein can cause non-specific interaction with Caspr2, the cells were also transfected with a pGL6-
XL4 plasmid expressing only the human IgG fc portion. The co-expression of TAG-1 was used as a 
positive control, as this co-IP was found always positive in this condition. The lysates were incubated 
with a protein-A coupled resin. To check also if proteins contained in FBS can non-specifically 
precipitate Caspr2, 1 ml of FBS was added to the lysate of cells expressing only Caspr2. The 
precipitated proteins were evaluated by western blotting using anti-HA antibodies to detect Caspr2. 
 
 
4.2 IDENTIFICATION OF NOVEL BINDING PARTNERS FOR 
CASPR2 AND NLGNs’ FAMILY MEMBERS 
 
4.2.1 Fishing experiments 
 As already mentioned, it is reasonable to think that Caspr2 and NLGN2 have 
binding partners not yet identified. In fact, Caspr2 has been found in other brain 
regions, like the synapse, where there’s no K+ channel clustering (Bakkaloglu et al., 
2008; Poliak et al., 1999; Zweier et al., 2009). In this case, it would likely exert other 
non-characterized functions and bind different proteins. Moreover, it has been 
reported in the first part of this thesis that the association between TAG-1 and Caspr2 
is not direct. In any case, it is likely that in-vivo they belong to the same molecular 
complex: if this is the case, their association has to be mediated by another unknown 
extracellular protein. Moreover, as long as TAG-1 is the only proposed molecular 
partner of the extracellular portion of Caspr2, the latter wouldn’t have a known 
binding partner. NLGN2, instead, shows several differences from the other family 
members both in the aminoacidic sequence and in the affinity for NRXNs (Südhof, 
2008; Comoletti et al., 2006), leading to the hypothesis that it has not yet identified 
associated proteins. 
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In order to identify uncharacterized binding partners of these two proteins, a 
fishing experiment was performed. This consisted of an affinity chromatography 
analysis of brain samples coupled with a mass spectrometry-based identification of 
the retained proteins. Briefly, the protein content of a small sample of adult and 
embryonic human prefrontal cortex (provided by a tissue bank) and of a rat brain 
were passed on a system of affinity chromatography columns, with different proteins 
bound to the stationary phase. These were: 
• IgC (IgG of Control), corresponding to the fc portion of a human IgG. It has 






In fig. 4.9 the scheme of the experiment is reported: the brain lysate was 
incubated with an IgC bound resin and loaded in a chromatography column to 
separate the beads from the unbound lysate. This step not only provides a control for 
the other IgG fusion proteins, but also allows to reduce the complexity of the sample, 
removing the proteins that would bind non-specifically either the resin or the IgG 
alone. The flow-through was incubated with a Caspr2-IgG-bound resin and the beads 
were then collected. Finally, the unbound fraction was split in three parts and each 
was incubated with a different resin (αNRXN1-IgG, NLGN2-IgG and NLGN1-IgG). 
In all the cases the beads were collected. The bound proteins were finally eluted and 
identified through mass spectrometry analysis. The scheme was designed in this way 
in order to balance three different aspects: to give the priority to the identification of 
Caspr2 ligands, to avoid the progressive depletion of the protein pool after each step 
and to maximize the use of precious material. NLGN1 was used as a control for 
NLGN2, being that they are both members of the same family, while αNRXN1 was 
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Figure 4.9: Scheme of the fishing experiment. 
 
 
About three thousands proteins were identified and each one was reported as 
an entry with an assigned value for each resin analyzed (tab. 4.1 for an example): this 
number reflects how many times a certain peptide was identified in that resin. 
Obviously, the higher the number is, more likely it is that the association observed is 
specific. The proteins were then selected and ranked using the following criteria: 
1. A value for the IgC column null or very close to 0; 
2. A high value for the Caspr2 or NLGN2 column, coupled with a very low value 
for the αNRXN1 or NLGN1 column respectively. Priority was given to the 
proteins identified with this criterion in more than one tissue, because it would 
reflect a supposedly more specific binding; 
3. A localization at least partially extracellular: both Caspr2 and NLGN2 are type 
I trans-membrane proteins with a big extracellular domain accounting for the 
functional bindings of the proteins. This study is therefore more interested in 
finding extracellular binding partners, than intracellular ones. 
 
Due to the variable conditions intrinsic in this kind of experiments it is not 
possible to set objective criteria for this ranking, so these have to be subjective and 
interpreted case by case, based also on the available information for the examined 
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proteins. The values for the NLGN1 protein found in the αNRXN1 column can also 
be considered a positive control and give some hints while evaluating the values of 
the other proteins: however, when considering this kind of control, it has to be taken 
into account that the NRXN1-NLGN1 binding has a high affinity and it’s not 
predictable how the values can change for looser binding. Moreover, it has to be 
considered that the pull-down of a protein in this kind of fishing experiment can 
reflect also a non-direct association, but, if this is the case, the bridging protein is 
expected to be present in the list of candidates. For all these reasons each possible 
interaction has to be confirmed. The list of the candidate proteins identified is 
reported in tables 4.1, 4.2 and 4.3. 
 
 
Human fetus - Identified Proteins      
Symbol Name IgC Caspr2 αNRXN1 NLGN1 NLGN2 
αNRXN1 αNeurexin 1 [Homo sapiens] 1 0 1037 320 7 
SFRP1 Secreted frizzled-related protein 1 [Homo sapiens] 0 30 5 2 0 
CPNE1 Copine-1 [Homo sapiens] 0 19 3 0 5 
CLU Clusterin (Apolipoprotein J) [Homo sapiens] 1 1 0 2 18 
GPC1 Glypican-1 [Homo sapiens] 8 3 6 79 3 
GPC2 Glypican-2 precursor [Homo sapiens] 0 5 0 68 0 
SDC3 Syndecan-3 [Homo sapiens] 2 0 0 62 1 
TNC Tenascin C [Homo sapiens] 8 2 0 47 0 
AGRN Agrin [Homo sapiens] 6 1 1 46 0 
NCAN Neurocan [Homo sapiens] 4 3 5 43 11 
VCAN Versican [Homo sapiens] 3 2 2 43 4 
TNR Tenascin R (restrictin, janusin) [Homo sapiens] 0 1 1 33 0 
SDC2 Syndecan-2 [Homo sapiens] 0 0 0 29 0 
TMEFF1 Isoform 1 of Tomoregulin-1 [Homo sapiens] 0 0 0 23 0 
SCUBE1 Signal peptide, CUB and EGF-like domain-containing protein 1 [Homo sapiens] 0 5 0 16 0 
SPON1 Spondin-1 [Homo sapiens] 0 0 0 13 0 
BCAN Brevican [Homo sapiens] 0 0 0 13 0 
SDC1 Syndecan-1 [Homo sapiens] 0 2 0 12 0 
SDC4 Syndecan-4 [Homo sapiens] 0 0 0 5 0 
 
Table 4.1: List of candidates identified by fishing in the Human Fetus brain sample. For each 
candidate, the values for the five columns are reported. The candidates are arranged into groups 
according to the protein they are predicted to bind to. White: the values for αNRXN1 are reported as a 
positive control; Green: candidates for the binding to Caspr2; Yellow: candidates for the binding to 
NLGN2; Cyan: candidates for the binding to NLGN1. The proteins are ordered according to their 
values for the predicted partner. 
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 Human adult - Identified Proteins 
     Symbol Name IgC Caspr2 αNRXN1 NLGN1 NLGN2 
CLU Clusterin (Apolipoprotein J) [Homo sapiens] 0 5 0 12 157 
APOE Apolipoprotein E [Homo sapiens] 0 0 0 0 12 
RENR Renin Receptor [Homo sapiens] 0 0 0 0 11 
TNR Tenascin R (restrictin, janusin) [Homo sapiens] 1 0 0 76 0 
VCAN Versican [Homo sapiens] 0 0 0 39 0 
BCAN Brevican [Homo sapiens] 0 0 0 39 0 
NCAN Neurocan [Homo sapiens] 0 0 0 37 0 
PTPRZ1 Receptor-type tyrosine-protein phosphatase zeta [human] 0 0 0 24 0 
Caspr1 Contactin associated protein 1 [Homo sapiens] 1 0 0 21 0 
CNTN1 Contactin 1 [Homo sapiens]  1 0 0 11 0 
 
Table 4.2: List of candidates identified by fishing in the Human Fetus brain sample. For each 
candidate, the values for the five columns are reported. The candidates are arranged into groups 
according to the protein they are predicted to bind to. Yellow: candidates for the binding to NLGN2; 




 Rat - Identified Proteins 
     Symbol Name IgC Caspr2 αNRXN1 NLGN1 NLGN2 
SFRP1 Secreted frizzled-related protein 1 [rat] 3 32 0 0 0 
NPTXR Neuronal pentraxin receptor [rat] 2 11 3 0 0 
TNR Tenascin R (restrictin, janusin) [rat] 7 12 8 351 6 
PTPRZ1 Receptor-type tyrosine-protein phosphatase zeta [rat] 0 2 5 138 0 
BCAN Brevican [rat] 0 2 4 63 3 
CNTN1 Contactin-1 [rat] 4 15 7 59 5 
VCAN Versican [rat] 0 2 0 15 0 
 
Table 4.3: List of candidates identified by fishing in the Human Fetus brain sample. For each 
candidate, the values for the five columns are reported. The candidates are arranged into groups 
according to the protein they are predicted to bind to. Green: candidates for the binding to Caspr2; 




What emerges form these data, is that some candidates for the binding of 
Caspr2 and NGN2 were identified, but the highest number of proteins was predicted 
to bind NLGN1: 
• Caspr2: SFRP1 (see par. 1.4.1 for a brief introduction) was found in two 
different tissues. Even if the values are not high, it can reflect a specific 
interaction. Other two candidate proteins have been identified. 
Section 4  Results 	  
	   73 
• NLGN2: two different apolipoproteins were found (see par. 1.4.2 and 1.4.3 for 
a brief introduction). One of the two, Clusterin, was found in two different 
tissues and with relatively high values. 
• NLGN1: although this protein has been included as a control for NLGN2, the 
experiments can be read vice versa with NLGN2 being used as a control for 
NLGN1. A protein that has high fishing values for this protein, but not for its 
control can be a specific partner. Even if this work is specifically aimed at the 
identification of new ligands for Caspr2 and NLGN2, in general the goal is to 
characterize molecular partners of proteins involved in ASD. Therefore, the 
high number of candidate proteins found in the NLGN1 column is very 
interesting. It is also noteworthy that most of the proteins identified are present 
in the results of all three experiments. If NLGN1 would be confirmed to 
associate with one of them, new information on its role could be provided. 
Moreover, some of the proteins found here are known to interact with each 
other (tab. 4.4). So it is possible that one of them binds directly NLGN1 and 
the others have been pulled-down as a larger complex. Of course, among these 
proteins, the candidate that most likely would present an actual interaction is 
TNR (see par. 1.4.4 for a brief introduction), because it is characterized by the 
highest values. Also interesting is the presence in the list of Caspr1 and its 
ligand CNTN1: even if this complex is mainly located at the paranodes (see 
also par. 1.2.4), recently Caspr1 has been found at the synapse (Santos et al., 
2012), thus a similar interaction could be possible. Moreover, CNTN1 has 
been reported to bind also TNR and PTPRZ1, also identified in this fishing 
experiment. 
 
Protein Known ligand References 
TNR 
TNC Anlar and Gunel-Ozcan, 2012 
CNTN1 Rathjen and Wolff, 1991; Zacharias et al. 2002 
Neurocan Milev et al.,1998 
Versican Aspberg et al.,1995 
Brevican Aspberg et al.,1997 
Syndecan Salmivirta et al.,1991 
CNTN1 
Caspr1 Faivre-Sarraillh et al., 2000 See also par. 1.2.4 
TNR Rathjen and Wolff, 1991; Zacharias et al. 2002 
PTPRZ1 Bouyain and Watkins, 2010 
Table 4.4: List of TNR and CNTN1 known ligands. 
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All the predicted ligands identified had to be tested to verify their binding 
potential. Therefore, experiments using only the two hypothetical ligands had to be 
performed, in order to prove that their association is direct and specific. The high 
amount of candidates makes this step impossible to be carried out in a short time 
without an efficient high-throughput system. Therefore, for each target few proteins 
were selected for validation: these are chosen among the proteins that could most 
likely result positive. They are reported in tab. 4.5 and they are SFRP1, CLU, APOE, 









SFRP1 Caspr2 30 / 32 
CLU NLGN2 18 157 / 
APOE NLGN2 / 12 / 
CNTN1 NLGN1 / 11 59 
TNR NLGN1 33 76 351 
 
Table 4.5: Summary of the five selected candidates. For each of them the predicted partner and the 
values observed in the	  corresponding column in the three brain samples are reported. 
 
 
For the validation step, co-IP experiments were performed. The protocol used 
is the one described in par. 4.1.3, whose reliability was tested by the co-
immunoprecipitation of NLGN1-639* and βNRXN-300* (fig. 4.6): this uses secreted 
proteins either co-expressed in the same cell or independently expressed. In some 
cases the proteins were tested also by means of ITC, which is a technique that uses 
soluble purified proteins. All the candidates that had to be tested are extracellular and 
all, except CNTN1, are naturally secreted from the cell: therefore, the full-length 
proteins could be used. CNTN1, instead, is a GPI-anchored protein, so a truncated 
form, which lacks the anchored residues and is consequently secreted, was studied. 
Moreover, while for co-IP purposes the fully glycosylated proteins were used, for ITC 
analysis purposes they were purified after the expression in HEK 293 Gnt1- cells, a 
strain that lacks the N-acetylglucosaminyltransferase-1 activity and therefore 
produces proteins with a reduced number of N-glycans: these proteins were used to 
reduce the complexity of the interactions to be observed, focusing only on the 
peptide-peptide interactions. 
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In all the cases, the sequence encoding the tested proteins, lacking the portion 
corresponding to the leader peptide, was cloned in the multiple cloning site of a 
modified pCMV6-XL4 vector (fig. 4.10), between the NotI and XbaI sites. A protein 
expressed using this plasmid has the following features: 
• Prolactin Leader Peptide (PLP): this is an efficient signal for the secretion of 
the protein and is removed when the protein is released; 
• FLAG tag at the N-terminal; 
• 3Cprotease cleavage sequence before a human IgG fc peptide at the C-
terminal: this tag can be used for western blot analysis, pull-down experiments 





Figure 4.10: Scheme of the modified portion of pCMV-XL4 vector after the cloning of a hypothetic 
cDNA between the sites NotI and XbaI. 
 
In the following sections the results of the experiments performed for the 
validation of the predicted associations are reported. 
 
4.2.2 Secreted Frizzled Related Protein 1 
In order to perform experiments on the binding ability of Secreted Frizzled 
Related Protein 1 (SFRP1) to verify its association to Caspr2, the coding sequence of 
the full-length protein was cloned in the pCMV6-XL4 vector (fig. 4.10). The resulting 
plasmid was tested, transfecting it in both HEK-293 and HEK-293 Gnt1- cells and 
evaluating the levels of protein expression and secretion in the culture medium by 
means of western blotting. As shown in fig. 4.11A, both kinds of cells correctly 
expressed SFRP1. The protein was also properly secreted in the cell medium. 
 To test if SFRP1 is able to bind Caspr2, co-IP experiments were performed. 
The two plasmids encoding FLAG-Caspr2-1261* and FLAG-SFRP1-wt-IgG were 
independently transfected in HEK-293 cells cultured in two different plates. After 24 
hours the two culture media were collected, mixed together and incubated with a 
protein-A-bound resin to pull-down SFRP1. The precipitated proteins were then 
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evaluated by western blotting, using anti-FLAG antibodies. As shown in fig. 4.11B no 
Caspr2 protein was present after the pull-down, while it was present in the media and, 
therefore, correctly expressed. Even if the SFRP1 band is not visible in the lane 
corresponding to the media sample, the enrichment of the protein after the 
immunoprecipitation proves that it was correctly expressed, secreted and pulled-
down. These results show that SFRP1 does not bind to Caspr2, as was instead 
predicted by the fishing data. 
 
 
	  	  	  	  	   	  
 
Figure 4.11: A) Check of expression and secretion of SFRP1 from HEK-293 and HEK-293 Gnt1- 
cells. The cells were transfected with the pCMV6-XL4 plasmid encoding SFRP1 and after 24 hours the 
media were analyzed by western blotting using anti-human IgG antibodies. Expected molecular 
weight: 35 kDa for SFRP1 + 30 kDa for the IgG tag. The apparent molecular weight for SFRP1 
expressed by HEK-293 cells is higher due to glycosylation; B) co-IP experiments for the couple of 
proteins Caspr2 and SFRP1. The two plasmids encoding FLAG-Caspr2-1261* and FLAG-SFRP1-wt-
IgG were independently transfected in HEK-293 cells cultured in two different plates. After 24 hours 
the two culture media were collected, mixed together and incubated with a protein-A-bound resin to 




To confirm this result, the purification of the protein was attempted in order to 
perform ITC experiments. For this purpose, a stable transfected HEK-293 Gnt1- cell 
line expressing the FLAG-SFRP1-wt-IgG protein from the pCMV6-XL4 vector was 
generated. Even if the protein was correctly expressed and secreted, as shown in fig. 
4.11A, no yield was obtained from the purification. This process involves an affinity 
chromatography, using a protein-A bound resin, followed by the elution of the protein 
upon  digestion with  3Cprotease  that separates  the  protein from  the  IgG  tag.  This 
B A 
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Figure 4.12: 3C protease digestion of SFRP1. Culture medium of HEK-293 Gnt1- cells stably 
transfected with the pCMV6-XL4 plasmid encoding SFRP1 was collected. The protein was purified by 
a pull-down performed using an anti-FLAG resin and eluted with an excess of FLAG peptide. The 
purified protein was then incubated over night with a 3C protease enzyme. The day after, the protein 
samples of the purification resin, of the pre-cleavage protein and of the digested one were analyzed by 
SDS-PAGE stained with Coomassie blue and immuno-blotted with anti-FLAG antibodies. Red circles: 
heavy and light chains of the anti-FLAG antibodies. Expected molecular weight: 35 kDa for SFRP1 + 
30 kDa for the IgG tag. 
 
 
digestion is a very sensible step: a low efficiency would affect the final yield of the 
whole purification process. To check if this was the case, the protein was purified 
using FLAG antibodies and then the digestion was carried out. Samples from each 
step were analyzed by SDS-PAGE stained with coomassie blue and by western 
blotting. As shown in fig. 4.12, in all the samples a large amount of undigested 
protein could be found, meaning that the resin retained part of the protein and that the 
digestion process was not totally efficient, as other digestions could instead be carried 
out to completion (data not shown). The digested protein, instead, was present after 
purification both before and after the 3Cprotease treatment, reflecting probably a 
partial self-digestion of the protein: in any case, this band is missing in the coomassie 
stained gel for the untreated sample, probably due to an amount of protein below the 
detection limit. Altogether, these results prove that the digestion did take place, but 
with low efficiency, possibly explaining the low yield of purified protein. The IgG 
fused protein could not be used in ITC experiments. The purification of the protein 
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could have been carried out using its FLAG tag, but in that case the un-cleaved 
proteins should have been eliminated, for example by protein-A precipitation: this 
step would reduce the concentration of the protein in any case. Therefore, to perform 
ITC experiments the protein should be expressed fused only to a FLAG-tag and then 
purified. 
In conclusion, even if the ITC experiments were not performed, the co-IP data 
did not confirm the binding with Caspr2 predicted by the fishing results. 
 
4.2.3 Clusterin 
 Clusterin (CLU) had to be further studied to confirm its association to 
NLGN2. Therefore, the coding sequence of the full-length protein was cloned in the 
pCMV6-XL4 (fig. 4.10). To verify the correct expression of the protein, HEK-293 
cells and HEK-293 Gnt1- cells were transfected with the generated plasmid and then 
the medium was collected to evaluate the protein content through western blotting. As 
shown in fig. 4.13 both cell lines correctly expressed CLU, also delivering it to the 
cell medium. This protein has a molecular weight of 80 kDa when un-cleaved, but 
after maturation it is cleaved in two halves of 40 kDa each, connected by disulfide 
bonds: in this case, the C-terminal half looks bigger because it is fused to a 30 kDa 
IgG tag. Moreover, the HEK-293 Gnt1- line performs a simplified glycosylation: 
therefore, since CLU is a heavily glycosylated protein, with carbohydrate accounting 
for approximately 20-25% of the total mass of the mature molecule (Stewart et al., 
2007), it appears smaller when produced in this kind of cells. 
To verify the potential binding of CLU to NLGN2, co-IP experiments were 
performed. The two plasmids encoding FLAG-NLGN2-616* and FLAG-CLU-wt-
IgG were co-transfected in HEK-293 cells. After 24 hours the culture medium was 
collected and incubated with a protein-A-bound resin to pull-down CLU. The proteins 
were then eluted and analyzed through western blotting, using anti-FLAG antibodies. 
As shown in fig. 4.14, both the cleaved and un-cleaved form of CLU were correctly 
pulled-down in the assay and NLGN2 was co-precipitated as well, showing a binding 
activity of the two proteins. The unexpected result is that the band corresponding to 
NLGN2 is weaker after the pull-down in comparison to the medium. When a high 
affinity complex is precipitated, the involved proteins are expected to be more 
concentrated  (as for NLGN1 and βNRXN1 in fig. 4.6). A reduction in the intensity of 
the band is then unusual and can reflect a low affinity interaction. 
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Figure 4.13: Check of expression and secretion of CLU from HEK-293 and HEK-293 Gnt1- cells. The 
cells were transfected with the pCMV6-XL4 plasmid encoding CLU and after 24 hours the media were 
analyzed by western blotting using anti-FLAG or anti-human IgG antibodies. Expected molecular 
weight: 50 kDa for the uncleaved CLU, 25 kDa for each of the two halves, the N-terminal and the C-
terminal, 30 kDa for the IgG tag. The apparent molecular weight for CLU expressed by HEK-293 cells 
is higher due to glycosylation. 
 
 
              
 
Figure 4.14: Co-IP experiments for the couple of proteins NLGN2 and CLU. The two plasmids 
encoding FLAG-NLGN2-616* and FLAG-CLU-wt-IgG were co-transfected in HEK-293 cells. After 
24 hours the culture medium was collected and incubated with a protein-A-bound resin to pull-down 
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Figure 4.15: Chromatogram of the purified CLU protein. The elution volumes of the peaks are 
reported, corresponding to about 100 kDa (12.8 ml) and 200 kDa (10.76 ml) proteins. The first peak, 
instead, results from the aggregation of the concentrated protein. 
 
 
To confirm the association between these two proteins, CLU and NLGN2 
were purified in a form devoid of carbohydrates: even if sugars account for a large 
portion of the protein, when CLU is de-glycosylated it is still correctly folded and 
functioning (Stewart et al., 2007) and can therefore be used. For this purpose, a stable 
transfected HEK-293 Gnt1- cell line expressing the FLAG-CLU-wt-IgG protein from 
the pCMV6-XL4 vector was generated. The secreted protein was purified from the 
culture medium using a protein-A affinity chromatography column. The elution step 
was carried out through the incubation of the bound resin with a GST-tagged 3C-
protease: then the pure protein was concentrated. A sample of the purified protein was 
analyzed by means of FPLC. In fig. 4.15 the resulting chromatogram is reported. Two 
peaks can be observed at 10.76 and 12.8 ml of elution, probably corresponding to a 
dimeric and tetrameric form of the protein, due to their small volume of elution that 
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reflect proteins around 100 kDa and 200 kDa in weight. The first peak, instead, is 
most likely the result of the aggregation of the concentrated protein. In fact, it is 
known that CLU, especially in the de-glycosylated form, tends to aggregate in 
solution. 
FLAG-NLGN2-616*, instead was expressed from the pCDNA3.1 in stable 
transfected HEK-293 Gnt1- and purified from the culture medium using an anti-
FLAG resin. A sample of the purified protein was analyzed by FPLC. In fig. 4.16 the 
chromatogram is reported: a single and symmetric peak was present at 12.08 ml of 
elution, corresponding to a protein about 120 kDa in mass, consistent with the dimeric 
form of NLGN2, whose truncated monomer has an expected molecular weight of 




Figure 4.16: Chromatogram of the purified NLGN2 protein. The elution volume of the peak is 
reported, corresponding to about 122 kDa proteins. 
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The purified proteins were used to perform ITC experiments. CLU was used 
as the titrant at a concentration of 200 µM, while NLGN2 was concentrated to 22 µM. 
In fig. 4.17 the results are reported. The curve shows a binding activity of the two 
proteins, but with a relatively low affinity (Kd = 1.2 µM): this characteristic would be 
consistent with the co-IP results. Moreover, this experiment revealed an endothermic 
reaction for the association of these two molecules, instead of the exothermic one 




Figure 4.17: Results of the ITC analysis using the proteins CLU, used as titrant at a concentration of 
200 µM, and NLGN2, used at a concentration of 22 µM. The curve in the top panel is the result of the 
difference between the CLU vs NLGN2 and CLU vs Buffer curves. Each point in the bottom panel is 
the integral of the corresponding spike in the top panel. The calculated values for stoichiometric ratio 
(N), Kd, ΔH and ΔS of the interaction are reported. 
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Altogether, these results confirm the binding of CLU and NLGN2, but some 
uncertainty still remains. For example, being that CLU is a molecular chaperone, 
could the binding be due to a partially unfolded population of the NLGN2 protein? 
Even if this was true, it would explain only the ITC results, obtained using purified 
and concentrated proteins, steps that can affect the folding status of a protein; the co-
IP results, instead, would be only partially affected, because the binding happens in an 
ex-vivo assay conducted in a physiologic environment. In vivo experiments could 
definitely overcome this issue. For example, the full-length NLGN2 receptor fused to 
a FLAG-tag can be expressed in HEK cells and the binding with a CLU-IgG protein 
secreted by other cells, evaluated by a	  cell-surface immuno-labeling assay. 
 
4.2.4 Apolipoprotein E 
Apolipoprotein E (APOE) had to be further studied to confirm its association 
to NLGN2. Therefore, the coding sequence of the full-length protein was cloned in 
the pCMV6-XL4 (fig. 4.10). To verify the correct expression of the protein, HEK-293 
cells and HEK-293 Gnt1- cells were transfected with the generated plasmid and then 
the medium was collected to evaluate the protein content through western blotting. As 
shown in fig. 4.18A, APOE was correctly expressed and secreted by both cell lines. 
 
 
Figure 4.18: A) Check of expression and secretion of APOE from HEK-293 and HEK-293 Gnt1- cells. 
The cells were transfected with the pCMV6-XL4 plasmid encoding APOE and after 24 hours the 
media were analyzed by western blotting using anti-human IgG antibodies. Expected molecular 
weight: 36 kDa for APOE + 30 kDa for the IgG tag. The apparent molecular weight for APOE 
expressed by HEK-293 cells is higher due to glycosylation; B) co-IP experiments for the couple of 
proteins NLGN2 and APOE. The two plasmids encoding FLAG-NLGN2-616* and FLAG-APOE-wt-
IgG were co-transfected in HEK-293 cells. After 24 hours the culture medium was collected and 
incubated with a protein-A-bound resin to pull-down APOE. The proteins were then eluted and 
analyzed through western blotting, using anti-FLAG antibodies.	  
B A 
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To verify the potential binding of APOE to NLGN2, co-IP experiments were 
performed. The two plasmids encoding FLAG-NLGN2-616* and FLAG-APOE-wt-
IgG were co-transfected in HEK-293 cells. After 24 hours the culture medium was 
collected and incubated with a protein-A-bound resin to pull-down APOE. The 
proteins were then eluted and analyzed through western blotting, using anti-FLAG 
antibodies. In fig. 4.18B the results are presented. The FLAG-APOE-IgG protein has 
a molecular weight very close to the one of NLGN2. Even if, in theory, it would be 
possible to distinguish them, the western blot analysis of the proteins revealed bands 
too close to be distinguished: in any case, the doublet that seems to appear before the 
co-IP is no longer present after it, lacking the upper band, corresponding to NLGN2. 
To confirm that the co-IP experiment’s result is negative, the immunoprecipitated 
protein should be run again using either a more concentrated gel or a lower amount of 
protein to increase the separation of the bands; another solution can be to clone the 
coding sequence of APOE in a vector not encoding the FLAG sequence, so the 
experiments could be performed using an APOE-IgG protein: this protein would have 
tags compatible with FLAG-NLGN2. 
In order to perform ITC experiments to have more insights on the ability of 
APOE and NLGN2 to interact, the two proteins were purified. For this purpose a 
stable transfected HEK-293 Gnt1- cell line expressing the FLAG-CNTN1-639*-IgG 
protein from the pCMV6-XL4 vector was generated. The secreted protein was 
purified from the culture medium using a protein-A affinity chromatography column. 
The elution step was carried out through the incubation of the bound resin with a 
GST-tagged 3C-protease: then the pure protein was concentrated. A sample of the 
purified protein was analyzed by means of FPLC. As it can be seen in fig. 4.19, the 
chromatogram presents two peaks: the first may correspond to aggregated protein, 
while the second, centered on 10.74 ml of elution volume corresponds to a complex 
with a total molecular weight of about 250 kDa. Because the expected molecular 
weight of APOE is 36 kDa, this reflects a multimeric form of APOE. The peak is not 
perfectly symmetric, suggesting that degraded forms of the protein can be also 
present. 
FLAG-NLGN2-616*, instead was expressed from the pCDNA3.1 in stable 
transfected HEK-293 Gnt1- and purified from the culture medium using an anti-
FLAG resin as reported in par. 4.2.3 (see also fig. 4.16). 
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Figure 4.19: Chromatogram of the purified APOE protein. The elution volume of the peak is reported, 





The purified proteins were used to perform ITC experiments. APOE was used 
as the titrant at the concentration of 120 µM, while NLGN2 was concentrated to 8 
µM. In fig. 4.20 the results are reported: the points look randomly scattered, not 
fitting any statistical model, pointing-out that no binding can be observed using this 
method. Thus, even if, as already discussed, the co-IP results are not reliable, the ITC 
experiment failed to confirm an association between APOE and NLGN2. 
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Figure 4.20: Results of the ITC analysis using the proteins APOE, used as titrant at a concentration of 
120 µM, and NLGN2, used at the concentration of 8 µM. Each point in the bottom panel is the integral 
of the correspondent spike in the top panel. No association has been found between the two proteins. 
 
 
4.2.5 Contactin 1 
 Due to DNA unavailability, the mouse Contactin 1 (CNTN1) was used to 
validate its binding to the human NLGN1. Both these proteins have been highly 
conserved during evolution, sharing a high homology between species: in fact an 
alignment of the protein sequences performed using the Lalign software provided on 
the expasy website (http://embnet.vital-it.ch/software/LALIGN_form.html) gives 
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95.8% of identity for the two CNTN1s and 96.6% of identity for the two NLGN1s. 
Even if the use of a human Contactin 1 would have been optimal, an association using 
these proteins was expected to be identified. 
The coding sequence of CNTN1-986* protein was cloned in the pCMV6-XL4 
vector (fig. 4.10). The resulting protein is truncated on the last residue of the last FN3 
domain (the domain organization of CNTN1 is similar to the one of TAG-1/CNTN2; 
see also fig. 1.6), before the region where the GPI anchor is bound, resulting then in a 
secreted protein. The generated plasmid was transfected in both HEK-293 and HEK-
293 Gnt1- cells and the levels of protein expression and secretion in the culture 
medium evaluated by means of western blotting. As shown in fig. 4.21, both kinds of 
cells correctly expressed the protein, but multiple bands corresponding to CNTN1 
appeared when the protein was produced and secreted by HEK-293 cells. On the 
contrary, only one band can be found when evaluating the CNTN1 content of the cell 
lysate, corresponding to the expected molecular weight of the protein, pointing out 
that the lower bands can be the product of some degradation event that happens in the 
media. Moreover, different band patterns could be seen when the western blot was 
performed using anti-FLAG or anti-human IgG antibodies, maybe due to a 
degradation happening on both sides of the protein. Nevertheless, these degraded 
forms of the protein account only for a small portion of the total amount. 
To test if CNTN1 is able to bind NLGN1, co-IP experiments were performed. 
For this purpose the coding sequence of CNTN1-986* protein was cloned in a 
different version of pCMV6-XL4 vector, bearing only the IgG tag but not also the 
FLAG. This was necessary because some of the degradation forms of CNTN1, 
generated when the protein is secreted by HEK-293 cells, have the same molecular 
weight of NLGN1 and both the proteins have a FLAG tag. The two plasmids 
encoding FLAG-NLGN1-639* and CNTN1-986*-IgG were independently 
transfected in HEK-293 cells cultured in two different plates. After 24 hours the two 
culture media were collected, mixed together and incubated with a protein-A bound 
resin to pull-down CNTN1. The precipitated proteins were then evaluated by western 
blotting, using anti-FLAG or anti-IgG antibodies. As reported in fig. 4.22, no band 
corresponding to NLGN1 is present after co-IP, even if it can be seen in the culture 
medium. As a control, CNTN1 was correctly expressed and pulled-down. Therefore, 
these results showed the lack of association between these proteins. 
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Figure 4.21: Check of expression and secretion of CNTN1 from HEK-293 and HEK-293 Gnt1- cells. 
The cells were transfected with the pCMV6-XL4 plasmid encoding CNTN1 and after 24 hours the 
media or the lysate of the HEK-293 cells were analyzed by western blotting using anti-FLAG or anti-
human IgG antibodies. Expected molecular weight: 110 kDa for CNTN1 + 30 kDa for the IgG tag. The 





Figure 4.22: Co-IP experiments for the couple of proteins NLGN1 and CNTN1. The two plasmids 
encoding FLAG-Caspr2-1261* and FLAG-SFRP1-wt-IgG were independently transfected in HEK-293 
cells cultured in two different plates. After 24 hours the two culture media were collected, mixed 
together and incubated with a protein-A-bound resin to pull-down CNTN1. The precipitated proteins 
were then evaluated by western blotting, using anti-FLAG (to detect NLGN1) or anti-human IgG (to 
detect CNTN1) antibodies. 
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To verify the co-IP data, the CNTN1 and NLGN1 proteins were purified. For 
this purpose a stable transfected HEK-293 Gnt1- cell line expressing the FLAG-
CNTN1-639*-IgG protein from the pCMV6-XL4 vector was generated. The secreted 
protein was purified from the culture medium using a protein-A affinity 
chromatography column. The elution step was carried out through the incubation of 
the bound resin with a GST-tagged 3C-protease: then the pure protein was 
concentrated. A sample of the purified protein was analyzed by FPLC. In fig. 4.23 the 
resulting chromatogram is reported. Two peaks are present: the biggest one is 
centered at 11.2 ml of eluted buffer, corresponding about to 200 kDa, reflecting thus a 
probable dimeric form; the second is eluted earlier and can be related to a small 
quantity of aggregated protein. The non-perfect symmetry of the former peak can 




Figure 4.23: Chromatogram of the purified CNTN1 protein. The elution volume of the peak is 
reported, corresponding to about 200 kDa proteins. The first peak, instead, results from the aggregation 
of the concentrated protein. 
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Figure 4.24: Results for the ITC analysis using the proteins CNTN1, used as titrant at a concentration 
of 82 µM, and NLGN1, used at the concentration of 9.8 µM. Each point in the bottom panel is the 




FLAG-NLGN1-639*, instead, was expressed from the pCDNA3.1 in stable 
transfected HEK-293 Gnt1- and purified from the culture medium using an anti-
FLAG resin. 
The purified proteins were used to perform ITC experiments. NLGN1 was 
used as the titrant at the concentration of 82 µM, while CNTN1 was concentrated to 
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9.8 µM. In fig. 4.24 the results are reported: the points look randomly scattered, not 
fitting any statistical model, pointing-out that no binding can be observed using this 
method. These results, therefore, did not confirm the association between CNTN1 and 
NLGN1, as already emerged by co-IP analysis. 
 
4.2.6 Tenascin-R 
 The last protein selected to confirm its predicted association was Tenascin R 
(TNR): the fishing data strongly suggest the binding of this protein to NLGN1. To test 
this prediction, the coding sequence of TNR was cloned in the pCMV6-XL4 (fig. 
4.10). The expression and secretion of this protein was tested only in HEK-293 cells 
as its purification wasn’t attempted. For this purpose, the cells were transfected with 
the generated plasmid and then the medium was collected to evaluate the protein 
content through western blotting. As shown in fig. 4.25A, TNR was correctly 
expressed and secreted. TNR has two major molecular forms, TNR 160 (160 kDa) 
and TNR 180 (180 kDa). Moreover, the two isoforms go through extensive process of 
glycosylation that raise their molecular weight (Anlar and Gunel-Ozcan, 2012, see 
also par. 1.4.4). Therefore, the doublet found here is consistent with what is reported 
in literature. 
 To test if TNR is able to bind NLGN1, co-IP experiments were performed. 
The two plasmids encoding FLAG-NLGN1-639* and FLAG-TNR-wt-IgG were 
independently transfected in HEK-293 cells cultured in two different plates. After 24 
hours the two culture media were collected, mixed together and incubated with a 
protein-A-bound resin to pull-down TNR. The precipitated proteins were then 
evaluated by western blotting, using anti-FLAG antibodies. As shown in fig. 4.25B, 
TNR was correctly expressed and both the 180 kDa and the 160 kDa forms were 
enriched after immunoprecipitation. NLGN1 was present in the culture medium, but 
the corresponding band is faint, at the limit of detection, while it’s missing after the 
co-IP, apparently suggesting a lack of association. If the binding between the two 
proteins had high affinity, NLGN1 should be enriched, as TNR is, and the band 
should be visible; if the association had a low affinity instead, no enrichment would 
be expected, as happened for CLU and NLGN2. This means that the low amount of 
NLNG1 can mask some kind of interactions: therefore the experiment should be 
performed again, using a more concentrated sample. Moreover, the purification of the 
protein, in order to perform ITC experiments, has not been performed yet: other 
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interesting data, necessary to confirm or exclude a binding with NLGN1, would 
emerge from that analysis. 
Altogether these data do not confirm, nor exclude the interaction of TNR with 





                                   
 
Figure 4.25: A) Check of expression and secretion of TNR from HEK-293 cells. The cells were 
transfected with the pCMV6-XL4 plasmid encoding SFRP1 and after 24 hours the medium was 
analyzed by western blotting using anti-human IgG antibodies. Expected molecular weight: 150 kDa 
for TNR + 30 kDa for the IgG tag. The apparent molecular weight is higher due to glycosylation; B) 
co-IP experiments for the couple of proteins	   NLGN1 and TNR.	   The two plasmids encoding FLAG-
NLGN1-639* and FLAG-TNR-wt-IgG were independently transfected in HEK-293 cells cultured in 
two different plates. After 24 hours the two culture medium were collected, mixed together and 
incubated with a protein-A-bound resin to pull-down TNR. The precipitated proteins were then 


















The aim of this thesis was to characterize new ligands of proteins involved in 
Autism Spectrum Disorder (ASD): among all the proteins associated with this disease 
the attention was focused on Caspr2 and NLGN2. A better understanding on the 
binding proprieties of these two molecules would shed new light on their function and 
help to understand their role in ASD. 
Caspr2 is localized at the juxtaparanodes, where it promotes the clustering of 
the shaker like K+ channel. In 2003, two groups proposed that the juxtaparanodal 
localization is guaranteed by the direct binding between Caspr2 and TAG-1 and since 
then several lines of research based their conclusions on this assumption. The 
evidence supporting this idea came from the fact that TAG-1 deficient mice have 
mislocalized Caspr2 proteins and vice versa. Moreover, co-immunoprecipitation (co-
IP) experiments performed on brain lysates and co-immunoprecipitation experiments 
carried out using lysates form HEK or CHO cells transfected with plasmids encoding 
the two proteins seemed to confirm those results (Poliak et al., 2003; Traka et al., 
2003; see also fig. 1.7 and 1.8). If the first two approaches only prove the involvement 
of Caspr2 and TAG-1 in the same macromolecular complex, the latter one pointed out 
a direct interaction between them. In particular, the two proteins were co-precipitated 
from the cell lysate only when they were co-expressed in the same cell, but not when 
they were expressed from different ones and then mixed together. These results were 
interpreted from the authors as a need for the Caspr2/TAG-1 complex to be formed in 
“cis”, or on the plasma membrane. Alternatively, the complex may have to be formed 
co-translationally in the endoplasmic reticulum (ER). A similar model was proposed 
for the Caspr1/CNTN1 complex: nevertheless, while Caspr1 cannot be translocated to 
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the plasma membrane and it is retained in the ER if it is not co-expressed with 
CNTN1 (Faivre-Sarrailh et al., 2000), Caspr2, when expressed alone, is correctly 
transported to the cell surface and also its truncated version, lacking the trans-
membrane domain, can be released in the culture medium (Falivelli et al., 2012). 
 In this thesis, experiments to characterize the interaction between Caspr2 and 
TAG-1 were reported. Isothermal Titration Calorimetry approaches were used to 
calculate the affinity of the binding; moreover, the putative complex was analyzed by 
size exclusion chromatography. In all cases no association was observed for these 
proteins. Both these techniques use soluble proteins, purified independently from each 
other: therefore, the need for the complex to be formed in the ER can, in principle, 
explain the negative results obtained in these biophysical experiments. 
 To overcome this issue, pull-down experiments were performed co-expressing 
truncated proteins in HEK cells: these molecules lack the trans-membrane domains 
and are therefore released. Using this approach, the extracellular domains of Caspr2 
and TAG-1, that are proposed to be responsible for the association, can be processed 
together in the ER and secreted as a complex in the culture medium. Nevertheless, 
also using this approach it was not possible to detect any association. Moreover, 
different, non-overlapping fragments of TAG-1 were used together with the 
extracellular domain of Caspr2 for pull down-experiments in HEK cells. As expected, 
the complex could be pulled-down from the cell lysates when the two proteins were 
co-expressed in the same cell, but not when they were expressed from different ones 
and then mixed together. All the fragments tested resulted to have the same potential 
to associate with Caspr2, similar also to the one of the full-length protein. This is an 
unexpected result: in fact, even if the binding involved all the extracellular domains of 
TAG-1, the binding is expected to be reduced when some portions are missing. 
 Altogether these results led to the idea that the protocol used to test the 
association generates false-positive artifacts. Therefore, pull-down experiments to 
validate the protocol were performed. The association between βNRXN1 and NLGN1 
was used as a positive control, while the NLGN1-G500A mutant, which presents an 
abolished βNRXNs binding activity, was used as a negative control. Moreover, the 
associations of Caspr2 with unrelated proteins, such as Clusterin, CNTN1 (that should 
bind specifically Caspr1 and not Caspr2) and Secreted Frizzled Related Protein 1, 
were used as additional negative controls. These experiments showed that, when the 
binding was evaluated in cell lysates after co-expression, all the controls presented a 
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positive result, independently of their actual binding potential. When evaluated in cell 
lysates after independent transfections or in the cells’ culture media, all the controls 
showed the expected results. 
In addition, other unpublished data of the Comoletti lab proved that ER-
resident chaperones, as for example Calnexin, can bridge the association between 
Caspr2 and TAG-1 when they are over-expressed in HEK cells. Altogether these data 
pointed out that the potential of artifact generation of the protocols that were used to 
test the direct association of the two proteins biased those experiments. The fact that, 
instead, no direct binding was detected using multiple other approaches, strongly 
indicates that this does not take place. Caspr2 and TAG-1, therefore, belong most 
likely to the same supramolecular complex, but their association is not likely direct. In 
fact, the flaws reported in the co-IP protocols using overexpressed proteins, would not 
affect, most likely, the pull-down experiments performed on brain lysates, nor the 
Caspr2 delocalization that was found in TAG-1 deficient mice. 
TAG-1 was currently the only proposed protein associated to the extracellular 
portion of Caspr2. Therefore, the finding that they don’t directly interact makes the 
latter a protein with no characterized ligands. Moreover, Caspr2 has been found in 
other localizations such as the axon initial segment (AIS) of pyramidal cells, a portion 
that unlike juxtaparanodes is devoid of myelin (Inda et al., 2006; Ogawa et al., 2008), 
and the synaptic terminals, even if it’s not clear if at the pre- or post- synaptic side. In 
these locations Caspr2 can exert different functions, maybe binding different proteins. 
Another protein that can have uncharacterized molecular partners is NLGN2: as all 
the other NLGNs, this molecule is located in the post-synaptic terminals and interacts 
with the NRXNs family members. Nevertheless, NLGN2 is uniquely located at 
inhibitory synaptic terminals, has the lowest affinity for NRXNs and the lowest 
sequence similarity to the other members of its family. For all these reasons, a fishing 
experiment was performed: this consisted of an affinity chromatography using Caspr2 
or NLGN2 as bait proteins, to capture their ligands in a brain lysate. The mass 
spectrometry analysis of the retained proteins can provide a list of candidates for the 
binding to these proteins. Among all the bound proteins, about ten likely candidates 
were found and three of them, chosen among those who had the highest chance to be 
actual ligands, were selected for further analysis: these were Secreted Frizzled 
Related Protein 1 (SFRP1), Clusterin (CLU) and Apolipoprotein E (APOE). Even if 
NLGN1 was included in the experiment only as a control for NLGN2, the results 
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emerging from the fishing using it as bait were interesting, with about eighteen 
candidates. As all the members of the NLGN family, also NLGN1 is associated to 
ASD and also the identification of new ligands for this protein would be interesting 
for the understanding of this disease. Therefore, other two candidates were selected 
for further analysis: Contactin 1 (CNTN1) and Tenascin R (TNR). 
The second step for the identification of new ligands for Caspr2, NLGN1 and 
NLGN2 consisted of the confirmation of the proposed interactions of the selected 
candidates. This goal was achieved performing both ITC analysis and co-IP 
experiments. The latter were carried out using the protocol that was validated in this 
work. Out of five candidates, only the interaction of Clusterin with NLGN2 could be 
confirmed, with a reported affinity of 1.2 µM and an endothermic binding reaction. 
In the future, the binding between CLU and NLGN2 has to be better 
characterized, and if confirmed, the potential biological meaning will have to be 
investigated. Moreover, the remaining candidates identified by fishing have to be 
validated. Till now, only five out of about twenty-five were possible to be tested. The 
validation step is long because every protein has to pass through several steps, 
including the cloning of the gene, the stable expression in HEK cells and the 
purification. A fast and reliable test would improve the amount of data that can be 
generated in a small amount of time, even more if it is suitable for high throughput 
screenings. A technique that could be considered uses an immunocytochemistry 
approach to prove the binding in cell culture. By Expressing in HEK cells one of the 
proteins to test as a trans-membrane molecule and providing the hypothetical ligand 
in a soluble form, the binding can be evaluated by co-localization 
immunofluorescence: this technique would have the advantage of being suitable to be 
performed using transiently expressed proteins, saving the time of protein 
purification, that would be performed only in case of positive association to evaluate 
by means of ITC the binding parameters, such as Kd and molar ratio. Moreover, 
giving multiple soluble proteins at a time, all fused with the same tag, this technique 
can become suitable for high throughput screenings: the candidates could be 
processed in groups and in the case of a positive result the single proteins composing 
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